

1
2
3 gim/c/c/man/Nelson_CIC_systematic_review_4_10_16_without_figures.docx
4 gim/c/c/man/Nelson_CIC_systematic_review_4_10_16_without_figures_CLEAN.docx
5 gim/c/c/man/Nelson_CIC_systematic_review_3_10_16_Fig1.tif thru Fig3D.tif
6 4-14-16
7
8 For re-submission to GUT
9

10
11
12 **Comparison of Efficacy of Pharmacological Treatments for**
13 **Chronic Idiopathic Constipation:**
14 **A Systematic Review and Network Meta-analysis**
15
16

17 **Alfred D. Nelson, M.B.B.S.**
18 **Michael Camilleri, M.D.**
19 **Sakkarin Chirapongsathorn, M.D., M.Sc.**
20 **Priya Vijayvargiya, M.D.**
21 **Nelson Valentin, B.S.**
22 **Andrea Shin, M.D., M.Sc.***
23 **Patricia J. Erwin**
24 **Zhen Wang, Ph.D.#**
25 **M. Hassan Murad, M.D.#**
26
27
28
29
30

31 From

32 Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) and
33 #Mayo Clinic Evidence-Based Practice Center, Mayo Clinic, Rochester, MN 55905
34 *Dr. Shin's current affiliation: Indiana University, Indianapolis, IN
35
36

37
38 **Running title:** Network meta-analysis of pharmacological agents for treatment of CIC
39

40 **Word count:** 3745 (excluding abstract, summary box, acknowledgements, disclosures,
41 references, table and figure legends)
42

43 **Key words:** bisacodyl, elobixibat, linaclotide, lubiprostone, picosulfate, polyethylene glycol,
44 prucalopride, tegaserod, velusetrag
45
46

47 **Abbreviations:**

48 chronic idiopathic constipation (CIC)
49 numbers needed to treat (NNT)
50 sodium picosulfate (NaP)
51 polyethylene glycol (PEG)
52 complete spontaneous bowel movements (CSBM)
53 spontaneous bowel movements (SBM)
54 weighted mean difference (WMD)
55 confidence interval (CI)
56
57
58

59
60 This is the author's manuscript of the article published in final edited form as:
Nelson, A. D., Camilleri, M., Chirapongsathorn, S., Vijayvargiya, P., Valentin, N., Shin, A., ... Murad, M. H.
(2016). Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic
review and network meta-analysis. Gut, gutjnl-2016-311835. <https://doi.org/10.1136/gutjnl-2016-311835>

1
2
3 serotonin or 5-hydroxytryptamine (5HT)
4 normal transit constipation (NTC)
5 slow transit constipation (STC)
6 high amplitude propagated contractions (HAPC)
7
8

9 **Address for correspondence:**

Michael Camilleri, M.D.
Mayo Clinic
200 First St. S.W.
Charlton Bldg., Rm. 8-110
Rochester, MN 55905
Tele: 507-266-2305
Email: camilleri.michael@mayo.edu
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis.

Data Sources: We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC.

Study Selection: Phase IIB and phase III randomized, placebo-controlled trials (RCT) of ≥ 4 weeks' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least 1 of 4 endpoints.

Data Extraction and Synthesis: Two investigators independently evaluated all full text articles that met inclusion criteria and extracted data for primary and secondary endpoints, risk of bias and quality of evidence.

Outcomes: Primary endpoints were ≥ 3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥ 1 CSBM/week. Secondary endpoints were change from baseline (Δ_b) in the number of SBM/week and Δ_b CSBM/week.

Results: Twenty-one RCTs (9189 patients) met inclusion and endpoint criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulphate (NaP). All pre-specified endpoints were unavailable in 4 polyethylene glycol studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥ 3 CSBM/week endpoint. No drug was superior at improving the primary endpoints on network meta-analysis. Bisacodyl appeared superior to the other drugs for the secondary endpoint, Δ_b in number of SBM/week.

1
2
3 **Conclusions:** Current drugs for CIC show similar efficacy. Bisacodyl may be superior to
4
5
6 prescription medications for Δ_b in the number of SBM/week in CIC.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

SUMMARY BOX

What is already known about this subject?

- Fifty percent of patients with chronic idiopathic constipation (CIC) are not completely satisfied with treatment, especially with fiber and laxatives.
- The number needed to treat (NNT), estimated from placebo-controlled clinical trials in CIC comparing pharmacological therapies to placebo, have been reported as follows: osmotic and stimulant laxative, NNT 3; lubiprostone, NNT 4; and prucalopride and linaclotide, both NNT 6.
- The absence of direct comparisons between different drug classes limits comparison of efficacy among treatments.

What are the new findings?

- Current drugs for CIC show similar efficacy for primary endpoints, which were ≥ 3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥ 1 CSBM/week.
- Bisacodyl may be superior to prescription medications for change from baseline (Δb) SBM/week in CIC and in comparison with some of the drugs in Δb CSBM/week.

How might it impact on clinical practice in the foreseeable future?

- Head-to-head trials of active agents are necessary to determine the optimal selection of pharmacological agents for CIC.
- Alternatively, first line medications for patients with CIC should be according to the pathophysiology in order to increase efficacy, such as prokinetics for patients with documented slow transit constipation in the absence of rectal evacuation disorders.

INTRODUCTION

The estimated global prevalence of chronic idiopathic constipation (CIC) in adults is 14%.^[1] It is usually diagnosed using Rome III symptom criteria,^[2] is about twice as common in women and more prevalent over 65 years of age, significantly impacts quality of life, and constitutes a significant financial burden.^[3] Treatment of constipation ^[4] usually starts with nonpharmacological agents like fiber (soluble in preference to nonsoluble fiber and is followed by pharmacological agents if there is no response to fiber.^[5] Polyethylene glycol, an osmotic laxative, increases the mean number of stools per week more effectively than placebo or lactulose in adults with CIC, based on direct meta-analyses.^[6] It is estimated that about 50% of patients with CIC were not completely satisfied with treatment due to lack of efficacy or safety concerns, especially with fiber and laxatives (both stimulant and osmotic).

Therefore, this appraisal of the relative efficacy of pharmacotherapies for chronic CIC is clinically relevant. The pharmacological classes of the medications used for CIC are: diphenyl methanes or derivatives (bisacodyl and sodium picosulphate), 5-HT₄ receptor agonists (prucalopride, tegaserod and velusetrag), guanylate cyclase C receptor agonist (linaclotide), chloride channel type 2 opener (lubiprostone) and apical sodium bile acid, (also known as ileal bile acid transport) inhibitor (elobixibat).

The numbers needed to treat (NNT), estimated from placebo-controlled clinical trials comparing these medications to placebo in CIC, were reported as follows: osmotic and stimulant laxative, NNT 3; lubiprostone, NNT 4; and prucalopride and linaclotide, both NNT 6.^[6] This might suggest differences in efficacy of the different drug classes; however, this assessment was based on failure to respond to therapy, and vastly different endpoints were used in individual studies.

1
2
3 The absence of direct comparisons between different drug classes limits comparison of
4 efficacy among treatments to the endpoints currently recommended by the US Food and Drug
5 Administration and is consistent with those of European Medicines Agency.[7] Therefore, our
6 aim was to compare the efficacy of drugs for CIC based on results of each drug compared to
7 placebo using Bayesian network meta-analysis and endpoints consistent with current regulatory
8 agency recommendations.

17 **METHODS**

19 This systematic review and network meta-analysis was performed according to guidance
20 provided by the Cochrane Handbook for Systematic Reviews of Interventions [8]. It is reported
21 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
22 (PRISMA) guidelines[9]. We followed an a priori established protocol.

29 **Search Methods for Identification of Studies**

31 A thorough database search was done in May 2015, using Ovid MEDLINE In-Process &
32 Other Non-Indexed Citations and Ovid MEDLINE (1946 to present), Ovid EMBASE, Scopus
33 databases (1988 to 2015) and Ovid Cochrane CENTRAL (to March 2015) for all the drugs used
34 for treatment of CIC. An expert librarian (PE) conducted the medical literature search with input
35 from the investigators. All the studies for this meta-analysis were identified using a combination
36 of subject headings and free text terms including constipation, chronic constipation, functional
37 constipation, lubiprostone, linaclotide, plecanatide, bisacodyl, sodium picosulfate (NaP),
38 prucalopride, velusetrag, naronapride, polyethylene glycol (PEG), lactulose, elobixibat, fiber,
39 and randomized placebo-controlled trial. Terms were searched in the title, abstract, original title,
40 name of substance word, subject heading word, keyword heading word, protocol supplementary
41 concept word, rare disease supplementary concept word, and unique identifier. The search was
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 conducted using combinations of these terms by using “and/or”. Multiple different combinations
4
5 of these terms were used. All the abstracts identified using the search strategy were
6
7 independently evaluated by two investigators (AN and NV) in order to select studies that were
8
9 eligible for inclusion. For those studies, full text articles were requested. Additional studies were
10
11 added after review of these drugs in the treatment of CIC in clinicaltrials.gov and manual review
12
13 of the citations in the publications. All the studies were independently identified by two
14
15 investigators using well-defined inclusion criteria; conflicts were resolved by consensus between
16
17 the two investigators after discussing with a third investigator (MC) with content expertise.
18
19

20 21 22 **Inclusion Criteria**

23
24 This systematic review and network meta-analysis was limited only to randomized,
25
26 placebo-controlled trials of drugs that are either approved by FDA for CIC or drugs with data
27
28 available for at least one pre-specified endpoint from phase IIB or III randomized, placebo-
29
30 controlled trials, and >4 weeks of treatment. Participants included were adults (>18 years of age)
31
32 who satisfied Rome II or Rome III criteria for (chronic) functional constipation.
33
34

35
36 There were no exclusions based on gender, sample size, medical condition, language
37
38 limitation or medications that are known to affect colonic transit or minimum follow-up period.
39
40 All eligible studies were required to have placebo as control intervention.
41
42

43 44 **Outcome Assessment**

45
46 The current recommended endpoint required by regulatory agencies (specifically, the
47
48 U.S. Food and Drug Administration) for demonstration of efficacy in CIC trials is ≥ 3 complete
49
50 spontaneous bowel movements (CSBM)/week and increase over baseline by ≥ 1 CSBM/week in
51
52 9 out of 12 weeks of treatment. However, only randomized, placebo-controlled trials of
53
54 linaclotide included this endpoint; therefore, we analyzed different endpoints that addressed
55
56
57
58
59
60

1
2
3 similar outcomes, in order to be consistent in appraising efficacy among studies. The primary
4 endpoints were the proportion of responders, based on ≥ 3 CSBM)/week or the proportion of
5 responders with increase over baseline by ≥ 1 CSBM/week. The secondary endpoints were
6 continuous, quantitative variables: the change from baseline (Δb) in the number of spontaneous
7 bowel movements (SBM)/week and Δb CSBM/week. Unfortunately, none of the four available
8 PEG trials included the endpoints selected for our network meta-analysis.
9
10
11
12
13
14
15
16

17 **Data Extraction and Management**

18
19 Data extraction from the eligible studies was performed by two independent investigators
20 (AN and SC) for the primary and secondary endpoints. Authors of the original publications were
21 contacted by email or by phone requesting missing data in the eligible studies. Data were
22 extracted from manuscripts or databases provided by the investigators or drug companies. Data
23 for primary endpoints were extracted as number of responders and non-responders for each
24 primary endpoint and mean and standard deviation for secondary endpoints.
25
26
27
28
29
30
31
32
33

34 We also collected data about characteristics of the randomized, placebo-controlled trials,
35 such as study center location (by continents); total number, age and gender of participants in the
36 intervention and control groups; type of intervention; duration of therapy; and criteria for a
37 diagnosis of constipation. Finally, data were extracted to appraise study quality, such as method
38 used for analysis of missing data and loss of follow-up in the intervention and control groups.
39
40
41
42
43
44
45

46 **Statistical Analysis**

47
48 We calculated relative risk for dichotomized outcomes, weighted mean difference
49 (WMD) for continuous outcomes, and related confidence intervals. We performed head-to-head
50 comparisons using DerSimonian-Laird random-effects model. We assessed statistical
51 heterogeneity using the I^2 statistic, which represents the proportion of heterogeneity that is not
52
53
54
55
56
57
58
59
60

1
2
3 the result of chance, but reflects true differences across study populations and interventions; I^2
4
5 >50% indicates substantial heterogeneity. Direct comparisons were performed using RevMan
6
7
8 v5.3 (The Nordic Cochrane Centre Copenhagen, Denmark).
9

10 Network meta-analyses were used to combine effect sizes for all possible comparisons
11
12 (direct and indirect), regardless of whether they had been compared in trials. In contrast to
13
14 traditional meta-analyses, which compare one intervention with another one at a time and
15
16 combine evidence directly from head-to-head clinical trials (if such trials exist), the network
17
18 meta-analyses allow comparison of all interventions simultaneously. A multivariate meta-
19
20 regression model developed by White was used.[10] The network meta-analyses were conducted
21
22 using the “network” suite in Stata Version 14.0 (StataCorp LP, College Station, TX, USA).[10]
23
24
25

26 27 **Sensitivity Analysis**

28
29 We examined the effects of the drugs for CIC based on relative risks of the primary and
30
31 secondary endpoints. We evaluated effect sizes based on therapeutic dose (standard dose group
32
33 versus high dose) and study quality for prucalopride (low risk of bias versus high risk of bias) for
34
35 CIC treatment. We also applied the “leave-one-out” method by excluding one study of 24 weeks
36
37 duration to evaluate the robustness of our findings.
38
39

40 41 **Assessment of Risk of Bias and Publication Bias**

42
43 Risk of bias was assessed using Cochrane Handbook for Assessing the Risk of Bias [9].
44
45 Two investigators (AN and PV) independently assessed the randomization schedule, allocation
46
47 concealment, blinding of participants and investigators, blinding of outcome assessment,
48
49 methods used for missing data, selective reporting, incomplete outcome data, risk of bias for
50
51 primary and secondary endpoints, and loss of follow up during the treatment period. Due to the
52
53
54
55
56
57
58
59
60

1
2
3 limited number of studies included in the analyses, we were not able to evaluate potential
4
5 publication bias.[11]
6

7 8 **Quality of Evidence** 9

10 We used the Grading of Recommendation, Assessment, Development and Evaluation
11 (GRADE) Approach to rate the quality of evidence for the estimates derived from the network
12 meta-analyses.[12] Since the studies included were only randomized, placebo-controlled trials,
13
14 the quality of evidence was considered high in the beginning and down rated based on the
15
16 assessment of risk of bias, inconsistency, indirectness, imprecision and publication bias. The
17
18 quality of evidence is rated as high, moderate, low and very low. For indirect estimates, the
19
20 rating usually starts at lowest rating of contributing direct evidence and can be further down
21
22 rated based on imprecision and indirectness (mainly intransitivity, i.e., difference in patient
23
24 populations between studies involved).
25
26
27
28
29
30

31 **RESULTS** 32

33 **Search Results** 34

35
36 The search strategy used identified 546 citations and, among these, we identified 114
37
38 articles for review for the full text appraisal. Among the 114 articles, only 18 articles met the
39
40 inclusion criteria; 96 studies did not meet the inclusion criteria, most often because the endpoints
41
42 in the trials were different from the selected primary and secondary endpoints, articles did not
43
44 have original data, or they were nonrandomized studies. The agreement between the
45
46 investigators (AN and NV) for selection of studies after full text review was high (Kappa statistic
47
48 0.86).
49
50
51

52
53 Three studies which were not identified by the search strategy were added by the
54
55 investigators. We contacted the authors and drug sponsors of these studies for additional
56
57
58
59
60

1
2
3 information regarding the primary and secondary endpoints, and their responses were added to
4
5 the analysis.
6

7
8 Figure 1 shows the schematic diagram of study selection for the systematic review and
9
10 meta-analysis; in total, 21 studies were eligible. The study characteristics are summarized in
11
12 Table 1.
13

14
15 There were 9189 patients in the 21 studies: 9 with prucalopride,[13, 14, 15, 16, 17, 18,
16
17 19, 20, 21] 3 with lubiprostone,[22, 23, 24] 3 with linaclotide,[25, 26, 27] 2 with tegaserod,[28,
18
19 29] 1 each with Velusetrag,[30] Elobixibat,[31] bisacodyl,[32] and sodium (Na)
20
21 picosulphate.[33] The number of drugs, sample size of each drug, and the number of clinical
22
23 trials included in the network meta-analysis are represented in the form of a network diagram
24
25 (Figure 2).
26
27

28
29 The risk of bias of the included studies is summarized in Table 2. Overall, quality was
30
31 high in 11, moderate in 9, and low in 1 study. Downgrading of quality was based most often on
32
33 unstated details regarding blinding, allocation concealment or management of missing data.
34
35

36 **Direct Meta-analysis**

37
38 The results of the direct meta-analysis for each primary and secondary endpoint are
39
40 summarized in Figure 3A-D.
41
42

43 *Primary Endpoints*

44
45 The data for responder analysis with ≥ 3 CSBM/week were available for 14 randomized,
46
47 placebo-controlled trials. All six drugs showed a significant increase in ≥ 3 CSBM/week when
48
49 compared to placebo. Among the three 5HT₄ agonists (prucalopride, velusetrag and tegaserod),
50
51 prucalopride showed higher efficacy [relative risk (RR)] of 1.85 with a 95% confidence interval
52
53 (CI) of 1.35 to 2.54 when compared to placebo and with significant heterogeneity of 80.8%
54
55
56
57
58
59
60

1
2
3 (p=0.0001). Velusetrag had an RR of 4.86 (95% CI, 2.02 to 11.71); the wider confidence interval
4
5 may suggest velusetrag might be less efficacious when compared to prucalopride. Stimulant
6
7 laxatives, bisacodyl and NaP, showed approximately similar efficacy. For linaclotide, RR was
8
9 1.96 (95% CI, 1.12 to 3.44). There was significant heterogeneity between studies of all the drugs
10
11 appraised using this endpoint ($I^2 = 77.4\%$ $P < 0.00001$).
12
13

14
15 For responder analysis with increase over baseline by ≥ 1 CSBM/week, data were
16
17 available for 15 randomized, placebo-controlled trials; all 7 of the drugs were superior to
18
19 placebo. Stimulant laxatives (bisacodyl and NaP) and elobixibat showed approximately similar
20
21 efficacy. Prucalopride showed superior efficacy among the 5HT₄ agonists, but the heterogeneity
22
23 between studies was significant ($I^2 = 74.5\%$, $p=0.0001$). Even though the RR for velusetrag was
24
25 3.10, which is relatively high when compared to the RR for prucalopride, the 95% CI with
26
27 velusetrag was wide (1.83 to 5.24) and overlapped that of prucalopride. Given the overlapping
28
29 95% CI for the two drugs and the significant heterogeneity in the efficacy of prucalopride, the
30
31 data show overall similar efficacy for prucalopride and velusetrag.
32
33
34

35 36 *Secondary Endpoints*

37
38 Data for Δ_b CSBM/week were available only for 5 drugs. All the drugs showed superior
39
40 efficacy when compared to placebo. Bisacodyl had a weighted mean difference (WMD) of 3.20
41
42 (95% CI, 2.66 to 3.74). Elobixibat and NaP had similar efficacy. For linaclotide, the WMD was
43
44 1.57, with heterogeneity I^2 of 0%; this WMD was greater than that of prucalopride which was
45
46 0.90 and was also associated with significant heterogeneity I^2 of 76.8%.
47
48
49

50
51 For the Δ_b SBM/week, all 7 of the drugs showed superior efficacy relative to placebo.
52
53 Bisacodyl showed higher efficacy with a WMD of 4.90 when compared to NaP (3.20).
54
55 Velusetrag, elobixibat and linaclotide showed similar efficacy with a mean difference (MD) in
56
57
58
59
60

1
2
3 the absolute number of Δ_b SBM/week of ~2.08. For prucalopride, the WMD was 2.03, with
4
5 significant heterogeneity of 63.9%. For lubiprostone, WMD was 1.91 with an I^2 of 23.4%.
6
7

8 **Network Meta-analysis**

9 10 Responder analysis for ≥ 3 CSBM/week (Table 3A)

11
12 Except for tegaserod, all the other drugs (bisacodyl, NaP, prucalopride, velusetrag,
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
linacotide and elobixibat) showed superior efficacy compared to placebo, but none of the drugs
showed superior efficacy when compared to each other in the network meta-analysis.

Responder analysis for increase over baseline by ≥ 1 CSBM/week (Table 3B)

Apart from tegaserod and linacotide, all the drugs (bisacodyl, NaP, prucalopride and
velusetrag) showed superior efficacy when compared to placebo, but none of the drugs showed
superior efficacy when compared to each other in the network meta-analysis, with the exception
of velusetrag which appears superior when compared to prucalopride and tegaserod.

Change in number of CSBM/week compared to baseline (Table 4A)

Bisacodyl, NaP, prucalopride, linacotide and elobixibat showed superior efficacy on the
 Δ_b CSBM/week when compared to placebo. On a network meta-analysis, bisacodyl was superior
to NaP, prucalopride and linacotide. Bisacodyl did not show significant efficacy over elobixibat
using this endpoint. NaP showed superior efficacy when compared to prucalopride.

Change in number of SBM/week compared to baseline (Table 4B)

When compared to placebo on a network meta-analysis, bisacodyl, NaP, prucalopride,
velusetrag, linacotide, elobixibat and lubiprostone treatment showed superior increase in
 Δ_b SBM/week.

1
2
3 Network meta-analysis suggested that bisacodyl is superior when NaP, prucalopride,
4 velusetrag, linaclotide, elobixibat and lubiprostone are compared to bisacodyl. NaP showed
5 superior efficacy when prucalopride and lubiprostone were compared to NaP.
6
7
8
9

10 **Quality of Evidence**

11
12 We applied the GRADE approach to the main outcome of ≥ 1 CSBM/week because it had
13 the largest number of included trials. In terms of direct estimates of drugs compared to placebo,
14 the quality of evidence was moderate or high for all comparisons. However, most head-to-head
15 comparisons were imprecise (i.e., their CIs were wide and overlapped the null effect). Therefore,
16 the quality of evidence of head-to-head comparisons was mostly low (Table 5).
17
18
19
20
21
22
23

24 **Sensitivity Analysis**

25
26 We conducted sensitivity analyses based on dose of medication (for all drugs for which at
27 least two doses were studied) and risk of bias (for prucalopride). Results were consistent between
28 standard therapeutic dose group compared to high and low dose groups for the primary endpoints
29 and for most of the secondary endpoint analyses (Table 6). An exception was that low dose (in
30 contrast to standard or high dose) prucalopride was not effective compared to placebo for the
31 endpoints of ≥ 3 CSBM/week and Δb SBM/week.
32
33
34
35
36
37
38
39
40

41 When analysis was restricted to prucalopride studies at low risk of bias, four trials [13, 16,
42 18, 19] were included and, for the two primary responder analyses, we noted that for
43 ≥ 3 CSBM/week, the RR was 2.12 (1.71, 2.63) and, for increase over baseline by ≥ 1
44 CSBM/week, the RR was 1.76 (1.54, 2.02); both had heterogeneity of 0%.
45
46
47
48
49

50 A third sensitivity analysis assessed whether any one study with a markedly different
51 duration [17] had a dominant effect on the pooled RR or heterogeneity. We found that this single
52 study did not markedly affect the summary estimate for the prucalopride studies. Thus, including
53
54
55
56
57
58
59
60

1
2
3 the study resulted in RRs for ≥ 3 CSBM/week and for increase over baseline by ≥ 1 CSBM/week
4
5 of 1.85 (I^2 80.8%) and 1.54 (I^2 74.3%), respectively; excluding the study, the RRs were 1.96 (I^2
6
7 81.8%) and 1.63 (I^2 66.4%), respectively.
8
9

10 **DISCUSSION**

11
12 Our study has shown that each drug used in the treatment of CIC is superior to placebo,
13
14 based on the published randomized, placebo-controlled trials. All the drugs are equally
15
16 efficacious for the primary endpoints of responder analysis with ≥ 3 CSBM/week and increase
17
18 over baseline by ≥ 1 CSBM/week, in the network meta-analysis. Bisacodyl may be superior to all
19
20 the other drugs in the secondary endpoint of Δ_b SBM/week and in comparison with some of the
21
22 drugs in Δ_b CSBM/week.
23
24
25

26
27 There are, however, limitations in this appraisal of relatively greater efficacy of
28
29 bisacodyl. There is only one bisacodyl trial with only 4 weeks of treatment compared to other
30
31 drugs which provided treatment for 12 or 24 weeks. Confirmation of superiority of any of these
32
33 pharmacotherapies requires direct comparisons of the active interventions using randomized,
34
35 placebo-controlled trials. A network meta-analysis has distinct features in the absence of trials of
36
37 direct comparisons of treatments, and may inform judicious selection of treatment. The
38
39 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recommends use
40
41 of multiple treatment meta-analyses in synthesis of data, even with nodal networks, as it allows
42
43 for more statistically sound assessment of comparative efficacy.[34]
44
45
46

47
48 Typically, patients in these randomized, placebo-controlled trials fulfilled Rome II or III
49
50 criteria for constipation after exclusion of medical and structural conditions.[35] These
51
52 symptom-based criteria do not differentiate groups, based on the pathophysiology causing CIC.
53
54
55 Based on a study of symptoms and pathophysiology in 1411 patients, subgroups of CIC were
56
57
58
59
60

1
2
3 identified, based on pathophysiology: normal transit constipation (NTC) in ~70%, dyssynergic
4 defecation in ~25%, and slow transit constipation (STC) in ~4.5%. [36] In fact, epidemiological
5 studies also have shown that about one-third of people in the community who experience
6 constipation endorse symptoms consistent with dyssynergic defecation.[4] With a preponderance
7 of CIC patients being female and having NTC, the similar efficacy to all the classes of drugs for
8 the treatment of CIC is not surprising.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Prior randomized, placebo-controlled trials included in this analysis did not subgroup patients according to pathophysiology; hence, we are unable to report efficacy in subgroups of CIC. It is conceivable that patients with STC might respond better to treatment with agents that have significant effects on colonic motor function. Several of the agents evaluated in this network meta-analysis accelerate colonic transit, including intestinal secretagogues (lubiprostone,[37] linaclotide,[38] and the bile acid transport inhibitor, elobixibat [39]) and prokinetic agents (prucalopride,[40] tegaserod,[41] and bisacodyl [42]). However, among all these drugs, only prucalopride [43] and bisacodyl have been shown to increase the number of high amplitude propagated contractions (HAPC), which are highly propulsive in the colon.[44] Lubiprostone did not induce colonic high amplitude contractions.[45]

A recent consensus monograph, based on meta-analysis of treatments of CIC, gave strong recommendation for treatment with fiber, osmotic laxatives (PEG, lactulose), stimulant laxatives (NaP and bisacodyl), prucalopride, linaclotide and lubiprostone.[46] However, the quality of evidence was considered moderate in some of the trials, there were no direct comparisons between active drugs, and the analysis used as primary endpoint the failure to respond to therapy. This appraisal actually combined in non-responder status failure to respond to different endpoints in each trial. In addition, the secondary endpoints evaluated did not differentiate SBM from

1
2
3 CSBM. Despite these methodological differences, our direct and network meta-analyses confirm
4
5 the general conclusion of the prior report regarding the efficacy of each intervention relative to
6
7 placebo with reference to the primary endpoints (which are the components of the endpoint
8
9 currently recommended by FDA), although there is a possible difference in efficacy on
10
11 secondary endpoints between bisacodyl and other drugs.
12
13

14
15 Our study has some limitations. There is only one randomized, placebo-controlled trial
16
17 for 4 of the drugs included in the meta-analysis (NaP, bisacodyl, velusetrag and elobixibat), and
18
19 osmotic laxatives such as PEG, lactulose, and magnesium salts were not included, since the
20
21 endpoints in those studies were not uniform or consistent with the inclusion criteria. This
22
23 particularly applies to the trials with PEG.[47, 48, 49, 50] There is one randomized, placebo-
24
25 controlled trial directly comparing PEG3350 + electrolytes (PEG3350+E) to prucalopride
26
27 treatment,[51] but this was a single-center study conducted in a controlled environment on
28
29 patients many of whom had features suggesting evacuation disorder at baseline: ~50% reported
30
31 sensation of anal blockage and 15% manual maneuvers to facilitate defecation. Moreover, the
32
33 primary endpoint was the proportion of patients having ≥ 3 SCBMs during the last week of
34
35 treatment in a 4-week trial, rather than the entire treatment period, and the randomized, placebo-
36
37 controlled trial showed non-inferiority of PEG3350 + E to prucalopride, consistent with our
38
39 general conclusion that the approved pharmacotherapies for CIC have similar efficacy.
40
41
42
43
44

45
46 Other limitations in our network meta-analysis are the variability in the duration of
47
48 treatment (4 to 24 weeks) and safety and adverse events for the drugs were not analyzed in our
49
50 study. Another limitation is that, in many of these pivotal clinical trials, bisacodyl is often used
51
52 as the rescue medication, and the impact of this on the “placebo” arms could not be appraised as
53
54 it is not reported in detail in the trials. It is also conceivable that the high number of prucalopride
55
56
57
58
59
60

1
2
3 trials impacted the relative assessment of efficacy by reducing the width of the confidence
4
5 interval of the RR; therefore, we have interpreted cautiously the RR differences between
6
7 prucalopride and velusetrag which was the only medication identified as less efficacious than
8
9 prucalopride in the statistical analysis.
10
11

12
13 Strengths in our study design and network meta-analysis include trials with similar
14
15 patient population, comparators, outcome assessments, and trial design; application of the
16
17 GRADE approach to provide an objective and transparent assessment of the quality of evidence
18
19 for evaluating comparative efficacy of these agents;[52] and the inclusion of the responder
20
21 analyses as well as secondary endpoints which are very relevant in view of differences in
22
23 baseline SBM and CSBM between studies.[53]
24
25
26

27
28 In conclusion, network meta-analysis shows that current pharmacotherapies for CIC have
29
30 similar efficacy. Based on secondary endpoints, bisacodyl may be superior to other medications
31
32 prescribed for CIC; however, bisacodyl is associated with abdominal cramps and diarrhea. In the
33
34 future, head-to-head trials of active agents are necessary to determine the efficacy and adverse
35
36 effects in order to facilitate optimal selection of pharmacological agents for CIC instead of the
37
38 current choice based on failure of prior drugs.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements: We thank Dr. Fabio Cataldi and Dr. Debra Silberg (Shire Pharmaceuticals, Turnhout, Belgium), the late Dr. Hans Graffner (Albireo, Göteborg, Sweden), Dr. Sabine Niedermeier (Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany), Dr. Peter Lichtlen (Sucampo AG, Bethesda, MD), Dr. Fukudo Shin (Tohoku University, Sendai, Japan), Dr. Michael A Kamm (University of Melbourne, Melbourne, Australia) and Dr. Stefan Mueller-Lissner (Lehrkrankenhaus der Charité, Universitätsmedizin, Berlin, Germany) for providing access to clinical trial data for medications reviewed in this article.

Funding: Dr. Camilleri is supported by grant R01-DK92179 from National Institutes of Health for studies on lower functional gastrointestinal disorders.

Competing Interests: Dr. Camilleri received grants for research on pharmacodynamics of prucalopride, velusetrag, elobixibat, linaclotide, and lubiprostone in the past decade. Dr. Camilleri serves as an advisor to Albireo, Rhythm, and Theravance, with compensation for his time serving as an advisor paid to his employer, Mayo Clinic, not to himself personally. The other authors have no competing interests.

Authors' contributions:

Alfred D. Nelson: concept development, data analysis, selection of articles, authorship
Michael Camilleri: concept development, data analysis, selection of articles, authorship
Sakkarin Chirapongsathorn: network meta-analysis, authorship
Priya Vijayvargiya: assessment of study quality, authorship
Nelson Valentin: selection of articles to be included after the literature search, authorship
Andrea Shin: analysis of data on 5HT₄ agonists, authorship
Patricia J. Erwin: literature search for systematic review, authorship
Zhen Wang: network meta-analysis, authorship
M. Hassan Murad: systematic review and network meta-analysis, authorship

References

- 1 Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation
2 in the community: systematic review and meta-analysis. *Am J Gastroenterol* 2011;106:1582-91;
3 quiz 1, 92.
- 4 Longstreth GF, Thompson WG, Chey WD, et al. Functional Bowel Disorders.
5 *Gastroenterology* 2006;130:1480-91.
- 6 Peery AF, Crockett SD, Barritt AS, et al. Burden of Gastrointestinal, Liver, and
7 Pancreatic Diseases in the United States. *Gastroenterology* 2015;149:1731-41.e3.
- 8 Bharucha AE, Pemberton JH, Locke III GR. American Gastroenterological Association
9 Technical Review on Constipation. *Gastroenterology* 2013;144:218-38.
- 10 Voderholzer WA, Schatke W, Muhldorfer BE, et al. Clinical response to dietary fiber
11 treatment of chronic constipation. *Am J Gastroenterol* 1997;92:95-8.
- 12 Ford AC, Soares NC. Effect of laxatives and pharmacological therapies in chronic
13 idiopathic constipation: systematic review and meta-analysis. *Gut* 2011;60:209-18.
14 [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
15 2014/02/WC500162134.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162134.pdf)
- 16 Higgins JP, Strene JAC. *Cochrane Handbook for Systematic Reviews of interventions* In:
17 Higgins JP and Green S ed. Available from www.cochrane-handbook.org.: The Cochrane
18 Collaboration; 2011.
- 19 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for
20 Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care
21 Interventions: Checklist and Explanations PRISMA Extension for Network Meta-analysis.
22 *Annals of Internal Medicine* 2015;162:777-84.
- 23 White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-
24 analysis: model estimation using multivariate meta-regression. *Research Synthesis Methods*
25 2012;3:111-25.
- 26 Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias
27 in meta-analyses: a large survey. *CMAJ* 2007;176:1091-6.
- 28 Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating
29 of confidence in effect estimates for a single outcome and for all outcomes. *Journal of Clinical
30 Epidemiology* 2013;66:151-7.
- 31 Camilleri M, Kerstens R, Rykx A, et al. A Placebo-Controlled Trial of Prucalopride for
32 Severe Chronic Constipation. *New England Journal of Medicine* 2008;358:2344-54.
- 33 Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with
34 severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a
35 double-blind, placebo-controlled clinical trial. *Digestion* 2003;67:82-9.
- 36 Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in
37 patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study.
38 *Neurogastroenterology & Motility* 2012;24:999-e541.
- 39 Müller-lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of
40 prucalopride in elderly patients with chronic constipation. *Neurogastroenterology & Motility*
41 2010;22:991-e255.
- 42 Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled
43 trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride.
44 *Neurogastroenterology & Motility* 2015;27:805-15.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 18 Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. *Alimentary Pharmacology & Therapeutics* 2009;29:315-28.
- 19 Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. *Gut* 2009;58:357-65.
- 20 Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. *Alimentary Pharmacology & Therapeutics* 2002;16:1347-56.
- 21 Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation. *Am J Gastroenterol* 2015;110:741-8.
- 22 Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Lubiprostone, a Locally-Acting Type-2 Chloride Channel Activator, in Patients With Chronic Constipation. *Am J Gastroenterol* 2008;103:170-7.
- 23 Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. *Dig Dis Sci* 2010;55:1090-7.
- 24 Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation. *Clinical Gastroenterology and Hepatology* 2015;13:294-301.e5.
- 25 Lacy BE, Schey R, Shiff SJ, et al. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. *PLoS ONE* 2015;10:e0134349.
- 26 Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of Linaclotide for Patients With Chronic Constipation. *Gastroenterology* 2010;138:886-95.e1.
- 27 Lembo AJ, Schneier HA, Shiff SJ, et al. Two Randomized Trials of Linaclotide for Chronic Constipation. *New England Journal of Medicine* 2011;365:527-36.
- 28 Fried M, Johanson JF, Gwee KA, et al. Efficacy of Tegaserod in Chronic Constipation in Men. *Am J Gastroenterol* 2007;102:362-70.
- 29 Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the Treatment of Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Multinational Study. *Am J Gastroenterol* 2005;100:362-72.
- 30 Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4-week, randomized, double-blind, placebo-controlled, dose–response study. *Alimentary Pharmacology & Therapeutics* 2010;32:1102-12.
- 31 Chey WD, Camilleri M, Chang L, et al. A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. *Am J Gastroenterol* 2011;106:1803-12.
- 32 Kamm MA, Mueller-Lissner S, Wald A, et al. Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation. *Clinical Gastroenterology and Hepatology* 2011;9:577-83.
- 33 Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients With Chronic Constipation. *Am J Gastroenterol* 2010;105:897-903.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 34 Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value Health* 2011;14:429-37.
- 35 Locke III GR, Pemberton JH, Phillips SF. AGA technical review on constipation. *Gastroenterology* 2000;119:1766-78.
- 36 Nullens S, Nelsen T, Camilleri M, et al. Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. *Gut* 2012;61:1132-9.
- 37 Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2006;290:G942-G7.
- 38 Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 Days Linaclotide on Transit and Bowel Function in Females With Constipation-Predominant Irritable Bowel Syndrome. *Gastroenterology* 2007;133:761-8.
- 39 Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional Constipation. *Am J Gastroenterol* 2011;106:2154-64.
- 40 Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. *Gastroenterology* 2001;120:354-60.
- 41 Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. *Gastroenterology* 2000;118:463-8.
- 42 Manabe N, Cremonini F, Camilleri M, et al. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. *Alimentary Pharmacology & Therapeutics* 2009;30:930-6.
- 43 Miner P, Camilleri M, Burton D, et al. Prucalopride induces high amplitude propagated contractions in the colon of patients with chronic constipation: A randomized study. *Neurogastroenterology and Motility* 2015;27:86-.
- 44 Preston DM, Lennard-Jones JE. Pelvic motility and response to intraluminal bisacodyl in slow-transit constipation. *Dig Dis Sci* 1985;30:289-94.
- 45 Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2009;296:G295-G301.
- 46 Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. *Am J Gastroenterol* 2014;109:S2-S26.
- 47 DiPalma JA, Cleveland MB, McGowan J, et al. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. *South Med J* 2007;100:1085-90.
- 48 DiPalma JA, Cleveland Mv, McGowan J, et al. A Randomized, Multicenter, Placebo-Controlled Trial of Polyethylene Glycol Laxative for Chronic Treatment of Chronic Constipation. *Am J Gastroenterol* 2007;102:1436-41.
- 49 Corazzari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. *Gut* 2000;46:522-6.

1
2
3
4 50 Corazziari E, Badiali D, Habib FI, et al.. Small volume isosmotic polyethylene glycol
5 electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. *Dig*
6 *Dis Sci* 1996;41:1636-42.

7 51 Cinca R, Chera D, Gruss HJ, et al. Randomised clinical trial: macrogol/PEG
8 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in
9 a controlled environment. *Alimentary Pharmacology & Therapeutics* 2013;37:876-86.

10 52 Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for
11 rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;349.

12 53 Bielefeldt K, Levinthal DJ, Nusrat S. Effective Constipation Treatment Changes More
13 Than Bowel Frequency: A Systematic Review and Meta-Analysis. *Journal of*
14 *Neurogastroenterology and Motility* 2016;22:31-45.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Study Characteristics

Study ID	Location	Drug	Doses tested	Study Duration (weeks)	Number Total: Intervention/control	Age (I)	Age (C)	Gender, F %	Constipation criteria
Camilleri 2008	USA	PRU	2mg, 4 mg QD	12	620: 411/209	48.0±14.3	48.9±13.0	87.1	≤2 CSBM/week for 6 months, and Rome III criteria#
Coremans 2003	Belgium	PRU	4 mg QD	4	53: 27/26	43.8±2.7	47.4±2.9	98.1	≥2 of the following for 6 months: 2 SBM/week and Rome III criteria#
Ke 2012	Asia-pacific	PRU	2mg QD	12	501: 249/252	41.4±12.9 2	41.8±12.9	90	≤2 SBM/week on average, and ≥1 of the following in Rome III criteria*
Mueller-Lissner 2010	Int	PRU	1mg, 2mg, 4 mg QD	4	300: 230/70	76.5±7.7	76±7.4	70.3	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria#
Piessevaux 2015	Europe	PRU	2mg QD	24	346: 177/169	49.4±15.8	48.3±16.3	14.7 ^s	≤2 CSBM/week and ≥1 of the following in Rome III criteria# for 6 months
Quigley 2009	USA	PRU	2mg, 4 mg QD	12	641: 429/212	48.9±13.9	46.2±13.0	86.6	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria# for 6 months
Tack 2009	Int	PRU	2mg, 4 mg QD	12	713: 473/240	44.1±15.1	43.7±15.3	90.8	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria# for 6 months
Emmanuel 2002	UK	PRU	1mg QD	4	74: 37/37	NA	NA	100	≤2 SBM/week and need to strain at least 25% of the defecation.
Yiannakou 2015	Europe	PRU	2mg QD	12	370: 184/186	58.4±17.6	58.5±16.3	0 ^f	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria# for 6 months
Goldberg 2010	USA	VEL	15mg, 30mg, 45mg QD	4	401: 294/107	44.4±11.7	45.4±10.0	92.0	≥18 years of age satisfying Rome 3 criteria functional constipation*
Fried 2007	Int	TEG	6mg bid	12	322: 158/164	51.1±17.1	51.8±17.2	0 ^f	≤3 CSBM/week and ≥1 of the following in Rome III criteria# for 6 months
Kamm 2005	Int	TEG	2mg, 6mg bid	12	1264: 848/416	46.3±15.2	46.0±15.6	86.3	≤3 CSBM/week and ≥1 of the following in Rome III criteria# for 6 months

Barish 2010	USA	LUBI	24mcg bid	4	237: 119/118	NK	NK	88.2	≤3 SBM/week and ≥1 of the following in Rome III criteria [#] for 6 months
Fukudo 2015	Japan	LUBI	24mcg bid	4	124: 62/62	42.7±16.4	41.5±14.2	88	Rome III criteria*, fewer than 3 defecations per week.
Johanson 2008	USA	LUBI	24mcg bid	4	244: 120/124	48.0±12.3	49.1±12.9	89.7	≤3 SBM/week and ≥1 of the following in Rome III criteria [#] for 6 months
Chey 2011	USA	ELO	5, 10, or 15mgQD	4	190: 143/47	47.6	49.9	89.5	<3 CSBM/week and ≥2 of the following in Rome III criteria*
Kamm 2011	UK	BIS	10mg QD	4	356: 239/117	55.8±15.9	54.7±15.1	74.7	< 3 CSBM/week and ≥1 of the following in Rome III criteria [#] for 6 months
Mueller-lissner 2010	Germany	NaP	10mg QD	4	362: 229/133	50.2±17.2	51.9±16.5	77.7	< 3 CSBM/week on average and ≥1 of the following in Rome III criteria [#] for 6 months
Lembo 2010	USA	LINA	75, 150, 300, or 600mcg QD	4	307: 239/68	47.6±13.1	46.1±15.6	92	<3 SBM/week and ≥1 of the following in Rome III criteria [#] at least 12 weeks during the 12 months preceding the study
Lembo 2011	USA	LINA	145 or, 290mcg, QD	12	643: 434/209	47.4±14.2	49.3±14.3	87.4	< 3 SBM/week and ≥1 of the following Rome criteria [#] for at least 12 weeks within the preceding 12 months
		LINA		12	633: 418/215	47.2±12.8	47.0±13.5	90.4	
Lacy 2015	USA	LINA	145 or, 290mcg, QD	12	487: 314/173	47.9	46.4	92.5	< 3 SBM/week and ≥1 of the following Rome criteria [#] for at least 12 weeks within the preceding 12 months

*- Rome III criteria which includes straining,

[#] - Part of the Rome III criteria which includes ≥25% straining, incomplete evacuation and hard/lumpy stools,

^{\$} - 85.32% were male, [¶] 100% were men,

PRU- Prucalopride, VEL- Velusetrag, TEG- Tegaserod, LUBI- Lubiprostone, ELO- Elobixibat, BIS- Bisacodyl, NaP- Sodium Picosulphate, LINA- Linaclotide, MC- Multicenter, SC- Single center, Int- International, I- Intervention, C- Control.

Table 2. Study Quality (CGR=computer generated randomization; Rx=intervention arm, C=control; LOCF=last observation carried forward; PRU=prucalopride, VEL=velusetrag, TEG=tegaserod, LUBI=lubiprostone, ELO=elobixibat, BIS=bisacodyl, NaP=sodium picosulphate, LINA=linaclotide)

Study Identification	Drug	Generation of randomization sequence	Allocation concealment	Double Blind	Lost to follow up	Methods used for missing data	Overall Quality
Camilleri 2008	PRU	Consecutive numbering + block randomization of 3	+	+	5Rx, 3C	Imputation	High
Coremans 2003	PRU	Unclear	Unclear	+	0	-	Mod
Ke 2012	PRU	CGR	+	+	3Rx, 2C	NS	Mod
Mueller-Lissner 2010	PRU	Randomization code generated by sponsor	+	+	0	Considered as non-responders	High
Piessevaux 2015	PRU	Randomization by web-based/voice-response system.	+	+	0	Imputation	Low
Quigley 2009	PRU	Block randomization of three	+	+	5Rx, 2C	Imputation	High
Tack 2009	PRU	Random allocation sequence by the investigator	Unclear	+	5Rx, 1C	Considered as non-responders	High
Emmanuel 2002	PRU	Method not known	Unclear	+	0Rx, 1C	NS	Mod
Yiannakou 2015	PRU	Central interactive web based response system	+	+	2Rx, 0C	Imputation	Mod
Goldberg 2010	VEL	Telephonic interactive voice response system using a permuted block algorithm	+	+	NK	LOCF	High
Fried 2007	TEG	Validated system that automated the random assignment by sponsor	+	+	0	-	High
Kamm 2005	TEG	Randomized using validated computer system	+	+	26Rx, 10C	NS	Mod
Barish 2010	LUBI	Block randomization of four	+	+	4Rx, 1C	LOCF	Mod
Fukudo 2015	LUBI	Method not known	Unclear	+	0	-	Mod
Johanson 2008	LUBI	Block randomization of four	+	+	1Rx, 2C	LOCF	Mod
Chey 2011	ELO	CGR by sponsor	+	+	1Rx, 0C	NS	Mod
Kamm 2011	BIS	CGR	+	+	0	-	High
Mueller-Lissner 2010	NaP	CGR	+	+	0	-	High
Lembo 2010	LINA	CGR using a block size of 5	+	+	3Rx, 0C	Observed-cases approach	Mod
Lembo 2011	LINA	CGR using a block size of 6	+	+	29Rx, 4C		High
Lacy 2015	LINA	Randomization by statistical programmer not involved in the trial	+	+	10Rx, 5C	Considered as non-responders	High

Table 3. Pooled RR, and 95% confidence intervals (for network meta-analysis) for primary endpoints (p<0.05 is bolded). (Note: For lubiprostone, both of the endpoints are not available +=Superior, -=Inferior).

3A. Responders with ≥ 3 CSBM per week for the drugs for CIC

Responders with ≥ 3 CSBM/week						
<i>Placebo</i>	2.46 (1.14, 5.31)	2.83 (1.27, 6.31)	1.84 (1.40, 2.43)	1.47 (0.7, 3.12)	4.86 (1.58, 14.99)	1.96 (0.8, 4.81)
	<i>Bisacodyl</i>	1.15 (0.38, 3.49)	0.75 (0.33, 1.69)	0.59 (0.20, 1.75)	1.97 (0.51, 7.72)	0.79 (0.24, 2.60)
		<i>Sodium picosulphate</i>	0.65 (0.28, 1.52)	0.52 (0.17, 1.56)	1.72 (0.43, 6.84)	0.69 (0.21, 2.31)
			<i>Prucalopride</i>	0.80 (0.36, 1.78)	2.64 (0.83, 8.41)	1.06 (0.41, 2.72)
				<i>Tegaserod</i>	3.30 (0.85, 12.79)	1.33 (0.41, 4.30)
					<i>Velusetrag</i>	0.40 (0.09, 1.70)
						<i>Linacotide</i>

3B. Responders with ≥ 1 CSBM per week for the drugs for CIC

Responders with increase over baseline by ≥ 1 CSBM/week							
<i>Placebo</i>	2.04 (1.3, 3.19)	2.03 (1.27, 3.23)	1.54 (1.30, 1.83)	1.33 (0.97, 1.83)	3.1 (1.61, 5.95)	1.72 (1.0, 2.96)	1.97 (1.09, 3.55)
	<i>Bisacodyl</i>	0.99 (0.52, 1.9)	0.76 (0.47, 1.22)	0.65 (0.38, 1.13)	1.52 (0.69, 3.35)	0.84 (0.42, 1.71)	0.96 (0.46, 2.02)
		<i>Sodium picosulphate</i>	0.76 (0.46, 1.25)	0.66 (0.37, 1.16)	1.53 (0.69, 3.41)	0.85 (0.42, 1.74)	0.97 (0.46, 2.06)
			<i>Prucalopride</i>	0.86 (0.60, 1.23)	2.01 (1.02, 3.93)	1.11 (0.63, 1.97)	1.27 (0.69, 2.35)
				<i>Tegaserod</i>	2.33 (1.13, 4.80)	1.29 (0.69, 2.42)	1.48 (0.76, 2.89)
					<i>Velusetrag</i>	0.56 (0.24, 1.30)	0.64 (0.26, 1.53)
						<i>Linacotide</i>	1.14 (0.51, 2.55)
							<i>Elobixibat</i>

Table 4. Pooled weighted mean difference, and 95% confidence intervals (for network meta-analysis) for Secondary endpoints (p<0.05 is bolded). (Note: Tegaserod both of the endpoints are not available, +=Superior, -=Inferior).

4A. Number of CSBM change from baseline for the drugs for CIC

# of CSBM/week change from baseline					
<i>Placebo</i>	3.2 (2.37, 4.03)	2.0 (1.19, 2.81)	0.9 (0.52, 1.28)	1.55 (0.90, 2.19)	1.99 (0.77, 3.22)
	<i>Bisacodyl</i>	-1.2 (-2.36, -0.04)	-2.3 (-3.22, -1.38)	-1.65 (-2.70, -0.60)	-1.21 (-2.69, -0.28)
		<i>Sodium picosulphate</i>	-1.10 (-1.99, -0.21)	-0.45 (-1.48, 0.58)	-0.01 (-1.47, 1.46)
			<i>Prucalopride</i>	0.65 (-0.10, 1.40)	1.09 (-0.19, 2.38)
				<i>Linaclotide</i>	0.44 (-0.94, 1.83)
					<i>Elobixibat</i>

4B. Number of SBM change from baseline for the drugs for CIC

# of SBM/week change from baseline							
<i>Placebo</i>	4.9 (3.90, 5.90)	3.20 (2.28, 4.12)	1.93 (1.45, 2.40)	2.07 (1.12, 3.01)	2.13 (1.54, 2.71)	2.08 (0.76, 3.41)	1.93 (1.30- 2.55)
	<i>Bisacodyl</i>	-1.7 (-3.05, -0.35)	-2.97 (-4.07, -1.87)	-2.83 (-4.20, -1.46)	-2.77 (-3.93, -1.62)	-2.82 (-4.48, -1.16)	-2.97 (-4.14- -1.79)
		<i>Sodium picosulphate</i>	-1.27 (-2.30, -0.24)	-1.13 (-2.45, 0.18)	-1.07 (-2.16, 0.01)	-1.12 (-2.73, 0.49)	-1.27 (-2.38- -0.16)
			<i>Prucalopride</i>	0.14 (-0.92, 1.20)	0.2 (-0.55, 0.95)	0.15 (-1.26, 1.56)	0 (-0.79- 0.79)
				<i>Velusetrag</i>	0.06 (-1.05, 1.17)	0.01 (-1.61, 1.64)	-0.14 (-1.27- 0.99)
					<i>Linaclotide</i>	-0.04 (-1.49, 1.40)	-0.2 (-1.05- 0.66)
						<i>Elobixibat</i>	-0.15 (-1.62- 1.31)
							<i>Lubiprostone</i>

Table 5. Quality of Evidence for Responders with ≥ 1 CSBM

(# -Inconsistency, ## -Severe inconsistency, \$ -Indirectness, \$\$ -Severe indirectness, * - Imprecision, ** - Severe imprecision, § -Risk of bias, p<0.05 is bolded)

Comparison	Direct	Quality of evidence	Indirect	Quality of evidence	Network	Quality of evidence
Bisacodyl v Placebo	2.04 (1.62, 2.57)	High	-	-	2.04 (1.3, 3.19)	High
Na P v Placebo	2.03 (1.56, 2.64)	High	-	-	2.03 (1.27, 3.23)	High
Prucalopride v Placebo	1.54 (1.28, 1.86)	Moderate [§]	-	-	1.54 (1.30, 1.83)	Moderate [§]
Tegaserod v Placebo	1.32 (1.14, 1.52)	High	-	-	1.33 (0.97, 1.83)	High
Velusetrag v Placebo	3.1 (1.83, 5.24)	High	-	-	3.1 (1.61, 5.95)	High
Linacotide v Placebo	1.72 (1.18, 2.52)	High	-	-	1.72 (1.0, 2.96)	High
Elobixibat v Placebo	1.97 (1.26, 3.07)	Moderate [§]	-	-	1.97 (1.09, 3.55)	Moderate [§]
Na P v Bisacodyl	-	-	0.99 (0.52, 1.9)	High	0.99 (0.52, 1.9)	Low**
Prucalopride v Bisacodyl	-	-	0.76 (0.47, 1.22)	Moderate	0.76 (0.47, 1.22)	Very Low**
Tegaserod v Bisacodyl	-	-	0.65 (0.38, 1.13)	High	0.65 (0.38, 1.13)	Low**
Velusetrag v Bisacodyl	-	-	1.52 (0.69, 3.35)	High	1.52 (0.69, 3.35)	Low**
Linacotide v Bisacodyl	-	-	0.84 (0.42, 1.71)	High	0.84 (0.42, 1.71)	Low**
Elobixibat v Bisacodyl	-	-	0.96 (0.46, 2.02)	Moderate	0.96 (0.46, 2.02)	Very Low**
Prucalopride v Na P	-	-	0.76 (0.46, 1.25)	Moderate	0.76 (0.46, 1.25)	Very Low**
Tegaserod v Na P	-	-	0.66 (0.37, 1.16)	High	0.66 (0.37, 1.16)	Low**
Velusetrag v Na P	-	-	1.53 (0.69, 3.41)	High	1.53 (0.69, 3.41)	Low**
Linacotide v Na P	-	-	0.85 (0.42, 1.74)	High	0.85 (0.42, 1.74)	Low**
Elobixibat v Na P	-	-	0.97 (0.46, 2.06)	Moderate	0.97 (0.46, 2.06)	Very Low**
Tegaserod v Prucalopride	-	-	0.86 (0.60, 1.23)	Moderate	0.86 (0.60, 1.23)	Very Low**
Velusetrag v Prucalopride	-	-	2.01 (1.02, 3.93)	Moderate	2.01 (1.02, 3.93)	Low*
Linacotide v Prucalopride	-	-	1.11 (0.63, 1.97)	Moderate	1.11 (0.63, 1.97)	Very Low**
Elobixibat v Prucalopride	-	-	1.27 (0.69, 2.35)	Moderate	1.27 (0.69, 2.35)	Very Low**
Velusetrag v Tegaserod	-	-	2.33 (1.13, 4.80)	High	2.33 (1.13, 4.80)	Moderate*
Linacotide v Tegaserod	-	-	1.29 (0.69, 2.42)	High	1.29 (0.69, 2.42)	Low**
Elobixibat v Tegaserod	-	-	1.48 (0.76, 2.89)	Moderate	1.48 (0.76, 2.89)	Very Low**
Linacotide v Velusetrag	-	-	0.56 (0.24, 1.30)	High	0.56 (0.24, 1.30)	Low**
Elobixibat v Velusetrag	-	-	0.64 (0.26, 1.53)	Moderate	0.64 (0.26, 1.53)	Very Low**
Elobixibat v Linacotide	-	-	1.14 (0.51, 2.55)	Moderate	1.14 (0.51, 2.55)	Very Low**

Table 6. Sensitivity analysis based on dose of medication (for primary endpoints NS if RR's 95% CI overlaps 1, for secondary endpoints NS if RR's 95% CI overlaps 0)

Drug	Responders with ≥ 3 CSBM			Responders with increase over baseline by ≥ 1 CSBM			Δb CSBM/wk			Δb SBM/wk		
	Standard	Low	High	Standard	Low	High	Standard	Low	High	Standard	Low	High
Bisacodyl v Placebo	2.46 (1.81, 3.35)	-	-	2.04 (1.62, 2.57)	-	-	3.2 (2.66, 3.74)	-	-	4.90 (4.14, 5.66)	-	-
Na P v Placebo	2.83 (1.93, 4.16)	-	-	2.03 (1.56, 2.64)	-	-	2.0 (1.51, 2.49)	-	-	3.20 (2.55, 3.85)	-	-
Prucalopride v Placebo	2.04 (1.59, 2.62)	1.31 (0.56, 3.04)	2.23 (1.74, 2.85)	1.54 (1.24, 1.92)	1.81 (1.23, 2.66)	1.71 (1.45, 2.01)	0.88 (0.49, 1.28)	1.30 (0.76, 1.84)	0.9 (0.42, 1.38)	1.58 (0.72, 2.44)	1.85 (0.79, 2.91)	1.63 (0.46, 2.81)
Tegaserod v Placebo	1.75 (1.32, 2.33)	1.18 (0.86, 1.62)	-	1.41 (1.18, 1.69)	1.17 (0.96, 1.42)	-	-	-	-	-	-	-
Velusetrag v Placebo	4.09 (1.59, 10.51)	5.57 (2.24, 13.86)	4.9 (1.93, 12.43)	2.49 (1.38, 4.46)	3.33 (1.91, 5.80)	3.5 (2.01, 6.10)	-	-	-	1.90 (1.23, 2.57)	2.20 (1.55, 2.85)	2.10 (1.35, 2.85)
Linaclotide v Placebo	1.92 (1.03, 3.57)	-	2.0 (1.08, 3.69)	1.64 (1.07, 2.51)	-	1.81 (1.19, 2.73)	1.45 (1.09, 1.82)	1.02 (0.22, 1.82)	1.70 (1.39, 2.01)	1.83 (1.18, 2.48)	-	2.26 (1.84, 2.68)
Elobixibat v Placebo	-	-	-	2.25 (1.42, 3.58)	1.74 (1.06, 2.87)	2.25 (1.42, 3.58)	1.46 (0.54, 2.38)	1.42 (0.25, 2.59)	3.09 (2.05, 4.13)	1.79 (0.72, 2.86)	1.18 (-0.06, 2.42)	3.27 (2.11, 4.43)
Lubiprostone v placebo	-	-	-	-	-	-	-	-	-	1.92 (1.35, 2.49)	-	-

1
2
3 Drug: Standard dose, Low dose, High dose. Prucalopride: 2mg QD, 1 mg QD, 4mg QD.

4
5 Velusetrag: 30mg QD, 15mg QD, 50mg QD. Tegaserod: 6mg bid, 2mg bid, no high dose.

6
7 Linaclotide: 145/150mcg QD, 75mcg QD, 290/600mcg QD.

8
9 Elobixibat: 10mg QD, 5mg QD, 15mg QD. Lubiprostone: 24mcg bid, no low and high dose.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

FIGURE LEGENDS

Figure 1: Flow diagram of included studies identified for systematic review.

Figure 2: Network diagram (CT=clinical trials, P=patients)

Figure 3: Comparisons between treatment vs. placebo of primary endpoints, ≥ 3 CSBM/week (panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from baseline (panel C) and change in SBM from baseline (panel D).




Figure 1. Flow diagram of included studies identified for systematic review.
254x190mm (300 x 300 DPI)




Figure 2. Network diagram (CT=clinical trials, P=patients)
254x190mm (300 x 300 DPI)

Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3A. Comparisons between treatment vs. placebo of primary endpoints, ≥ 3 CSBM/week (panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from baseline (panel C) and change in SBM from baseline (panel D).
254x190mm (300 x 300 DPI)




Figure 3B. Comparisons between treatment vs. placebo of primary endpoints, ≥ 3 CSBM/week (panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from baseline (panel C) and change in SBM from baseline (panel D).
254x190mm (300 x 300 DPI)




Figure 3C. Comparisons between treatment vs. placebo of primary endpoints, ≥ 3 CSBM/week (panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from baseline (panel C) and change in SBM from baseline (panel D).
254x190mm (300 x 300 DPI)




Figure 3D. Comparisons between treatment vs. placebo of primary endpoints, ≥ 3 CSBM/week (panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from baseline (panel C) and change in SBM from baseline (panel D).
254x190mm (300 x 300 DPI)

gim/c/c/man/Nelson_CIC_systematic_review_4_10_16_without_figures.docx
gim/c/c/man/Nelson_CIC_systematic_review_4_10_16_without_figures_CLEAN.docx
gim/c/c/man/Nelson_CIC_systematic_review_3_10_16_Fig1.tif thru Fig3D.tif
4-14-16
For re-submission to GUT

**Comparison of Efficacy of Pharmacological Treatments for
Chronic Idiopathic Constipation:
A Systematic Review and Network Meta-analysis**

**Alfred D. Nelson, M.B.B.S.
Michael Camilleri, M.D.
Sakkarin Chirapongsathorn, M.D., M.Sc.
Priya Vijayvargiya, M.D.
Nelson Valentin, B.S.
Andrea Shin, M.D., M.Sc.*
Patricia J. Erwin
Zhen Wang, Ph.D.#
M. Hassan Murad, M.D.#**

From

Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) and

[#]Mayo Clinic Evidence-Based Practice Center, Mayo Clinic, Rochester, MN 55905

*Dr. Shin's current affiliation: Indiana University, Indianapolis, IN

Running title: Network meta-analysis of pharmacological agents for treatment of CIC

Word count: 3745 (excluding abstract, summary box, acknowledgements, disclosures, references, table and figure legends)

Key words: bisacodyl, elobixibat, linaclotide, lubiprostone, picosulfate, polyethylene glycol, prucalopride, tegaserod, velusetrag

Abbreviations:

[chronic idiopathic constipation \(CIC\)](#)

[numbers needed to treat \(NNT\)](#)

[sodium picosulfate \(NaP\)](#)

[polyethylene glycol \(PEG\)](#)

[complete spontaneous bowel movements \(CSBM\)](#)

[spontaneous bowel movements \(SBM\)](#)

[weighted mean difference \(WMD\)](#)

[confidence interval \(CI\)](#)

1
2
3
4 [serotonin or 5-hydroxytryptamine \(5HT\)](#)
5 [normal transit constipation \(NTC\)](#)
6 [slow transit constipation \(STC\)](#)
7 [high amplitude propagated contractions \(HAPC\)](#)
8

9 **Address for correspondence:**

10 Michael Camilleri, M.D.
11 Mayo Clinic
12 200 First St. S.W.
13 Charlton Bldg., Rm. 8-110
14 Rochester, MN 55905
15 Tele: 507-266-2305
16 Email: camilleri.michael@mayo.edu
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis.

Data Sources: We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC.

Study Selection: Phase IIB and phase III randomized, placebo-controlled trials (RCT) of ≥ 4 weeks' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least 1 of 4 endpoints.

Data Extraction and Synthesis: Two investigators independently evaluated all full text articles that met inclusion criteria and extracted data for primary and secondary endpoints, risk of bias and quality of evidence.

Outcomes: Primary endpoints were ≥ 3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥ 1 CSBM/week. Secondary endpoints were change from baseline (Δ_b) in the number of SBM/week and Δ_b CSBM/week.

Results: Twenty-one RCTs (9189 patients) met inclusion and endpoint criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulphate (NaP). All pre-specified endpoints were unavailable in 4 polyethylene glycol studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥ 3 CSBM/week endpoint. No drug was superior at improving the primary endpoints on network meta-analysis. Bisacodyl appeared superior to the other drugs for the secondary endpoint, Δ_b in number of SBM/week.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: Current drugs for CIC show similar efficacy. Bisacodyl may be superior to prescription medications for Δ_b in the number of SBM/week in CIC.

Confidential: For Review Only

SUMMARY BOX

What is already known about this subject?

- Fifty percent of patients with chronic idiopathic constipation (CIC) are not completely satisfied with treatment, especially with fiber and laxatives.
- The number needed to treat (NNT), estimated from placebo-controlled clinical trials in CIC comparing pharmacological therapies to placebo, have been reported as follows: osmotic and stimulant laxative, NNT 3; lubiprostone, NNT 4; and prucalopride and linaclotide, both NNT 6.
- The absence of direct comparisons between different drug classes limits comparison of efficacy among treatments.

What are the new findings?

- Current drugs for CIC show similar efficacy for primary endpoints, which were ≥ 3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥ 1 CSBM/week.
- Bisacodyl may be superior to prescription medications for change from baseline (Δb) SBM/week in CIC and in comparison with some of the drugs in Δb CSBM/week.

How might it impact on clinical practice in the foreseeable future?

- Head-to-head trials of active agents are necessary to determine the optimal selection of pharmacological agents for CIC.
- Alternatively, first line medications for patients with CIC should be according to the pathophysiology in order to increase efficacy, such as prokinetics for patients with documented slow transit constipation in the absence of rectal evacuation disorders.

INTRODUCTION

The estimated global prevalence of chronic idiopathic constipation (CIC) in adults is 14%. [1] It is usually diagnosed using Rome III symptom criteria, [2] is about twice as common in women and more prevalent over 65 years of age, significantly impacts quality of life, and constitutes a significant financial burden. [3] Treatment of constipation [4] usually starts with nonpharmacological agents like fiber (soluble in preference to nonsoluble fiber and is followed by pharmacological agents if there is no response to fiber. [5] Polyethylene glycol, an osmotic laxative, increases the mean number of stools per week more effectively than placebo or lactulose in adults with CIC, based on direct meta-analyses. [6] It is estimated that about 50% of patients with CIC were not completely satisfied with treatment due to lack of efficacy or safety concerns, especially with fiber and laxatives (both stimulant and osmotic).

Therefore, this appraisal of the relative efficacy of pharmacotherapies for chronic CIC is clinically relevant. The pharmacological classes of the medications used for CIC are: diphenyl methanes or derivatives (bisacodyl and sodium picosulphate), 5-HT₄ receptor agonists (prucalopride, tegaserod and velusetrag), guanylate cyclase C receptor agonist (linaclotide), chloride channel type 2 opener (lubiprostone) and apical sodium bile acid, (also known as ileal bile acid transport) inhibitor (elobixibat).

The numbers needed to treat (NNT), estimated from placebo-controlled clinical trials comparing these medications to placebo in CIC, were reported as follows: osmotic and stimulant laxative, NNT 3; lubiprostone, NNT 4; and prucalopride and linaclotide, both NNT 6. [6] This might suggest differences in efficacy of the different drug classes; however, this assessment was based on failure to respond to therapy, and vastly different endpoints were used in individual studies.

1
2
3 The absence of direct comparisons between different drug classes limits comparison of
4 efficacy among treatments to the endpoints currently recommended by the US Food and Drug
5 Administration and is consistent with those of European Medicines Agency.[7] Therefore, our
6 aim was to compare the efficacy of drugs for CIC based on results of each drug compared to
7 placebo using Bayesian network meta-analysis and endpoints consistent with current regulatory
8 agency recommendations.

17 **METHODS**

19 This systematic review and network meta-analysis was performed according to guidance
20 provided by the Cochrane Handbook for Systematic Reviews of Interventions [8]. It is reported
21 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
22 (PRISMA) guidelines[9]. We followed an a priori established protocol.

29 **Search Methods for Identification of Studies**

31 A thorough database search was done in May 2015, using Ovid MEDLINE In-Process &
32 Other Non-Indexed Citations and Ovid MEDLINE (1946 to present), Ovid EMBASE, Scopus
33 databases (1988 to 2015) and Ovid Cochrane CENTRAL (to March 2015) for all the drugs used
34 for treatment of CIC. An expert librarian (PE) conducted the medical literature search with input
35 from the investigators. All the studies for this meta-analysis were identified using a combination
36 of subject headings and free text terms including constipation, chronic constipation, functional
37 constipation, lubiprostone, linaclotide, plecanatide, bisacodyl, sodium picosulfate (NaP),
38 prucalopride, velusetrag, naronapride, polyethylene glycol (PEG), lactulose, elobixibat, fiber,
39 and randomized placebo-controlled trial. Terms were searched in the title, abstract, original title,
40 name of substance word, subject heading word, keyword heading word, protocol supplementary
41 concept word, rare disease supplementary concept word, and unique identifier. The search was
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 conducted using combinations of these terms by using “and/or”. Multiple different combinations
4
5 of these terms were used. All the abstracts identified using the search strategy were
6
7
8 independently evaluated by two investigators (AN and NV) in order to select studies that were
9
10 eligible for inclusion. For those studies, full text articles were requested. Additional studies were
11
12 added after review of these drugs in the treatment of CIC in clinicaltrials.gov and manual review
13
14 of the citations in the publications. All the studies were independently identified by two
15
16 investigators using well-defined inclusion criteria; conflicts were resolved by consensus between
17
18 the two investigators after discussing with a third investigator (MC) with content expertise.
19
20
21

22 **Inclusion Criteria**

23
24 This systematic review and network meta-analysis was limited only to randomized,
25
26 placebo-controlled trials of drugs that are either approved by FDA for CIC or drugs with data
27
28 available for at least one pre-specified endpoint from phase IIB or III randomized, placebo-
29
30 controlled trials, and >4 weeks of treatment. Participants included were adults (>18 years of age)
31
32 who satisfied Rome II or Rome III criteria for (chronic) functional constipation.
33
34
35

36 There were no exclusions based on gender, sample size, medical condition, language
37
38 limitation or medications that are known to affect colonic transit or minimum follow-up period.
39
40 All eligible studies were required to have placebo as control intervention.
41
42
43

44 **Outcome Assessment**

45
46 The current recommended endpoint required by regulatory agencies (specifically, the
47
48 U.S. Food and Drug Administration) for demonstration of efficacy in CIC trials is ≥ 3 complete
49
50 spontaneous bowel movements (CSBM)/week and increase over baseline by ≥ 1 CSBM/week in
51
52 9 out of 12 weeks of treatment. However, only randomized, placebo-controlled trials of
53
54
55
56
57
58
59
60
linaclotide included this endpoint; therefore, we analyzed different endpoints that addressed

1
2
3 similar outcomes, in order to be consistent in appraising efficacy among studies. The primary
4 endpoints were the proportion of responders, based on ≥ 3 CSBM)/week or the proportion of
5 responders with increase over baseline by ≥ 1 CSBM/week. The secondary endpoints were
6 continuous, quantitative variables: the change from baseline (Δb) in the number of spontaneous
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

responders with increase over baseline by ≥ 1 CSBM/week. The secondary endpoints were continuous, quantitative variables: the change from baseline (Δb) in the number of spontaneous bowel movements (SBM)/week and Δb CSBM/week. Unfortunately, none of the four available PEG trials included the endpoints selected for our network meta-analysis.

Data Extraction and Management

Data extraction from the eligible studies was performed by two independent investigators (AN and SC) for the primary and secondary endpoints. Authors of the original publications were contacted by email or by phone requesting missing data in the eligible studies. Data were extracted from manuscripts or databases provided by the investigators or drug companies. Data for primary endpoints were extracted as number of responders and non-responders for each primary endpoint and mean and standard deviation for secondary endpoints.

We also collected data about characteristics of the randomized, placebo-controlled trials, such as study center location (by continents); total number, age and gender of participants in the intervention and control groups; type of intervention; duration of therapy; and criteria for a diagnosis of constipation. Finally, data were extracted to appraise study quality, such as method used for analysis of missing data and loss of follow-up in the intervention and control groups.

Statistical Analysis

We calculated relative risk for dichotomized outcomes, weighted mean difference (WMD) for continuous outcomes, and related confidence intervals. We performed head-to-head comparisons using DerSimonian-Laird random-effects model. We assessed statistical heterogeneity using the I^2 statistic, which represents the proportion of heterogeneity that is not

1
2
3 the result of chance, but reflects true differences across study populations and interventions; I^2
4
5 >50% indicates substantial heterogeneity. Direct comparisons were performed using RevMan
6
7 v5.3 (The Nordic Cochrane Centre Copenhagen, Denmark).
8
9

10 Network meta-analyses were used to combine effect sizes for all possible comparisons
11 (direct and indirect), regardless of whether they had been compared in trials. In contrast to
12 traditional meta-analyses, which compare one intervention with another one at a time and
13 combine evidence directly from head-to-head clinical trials (if such trials exist), the network
14 meta-analyses allow comparison of all interventions simultaneously. A multivariate meta-
15 regression model developed by White was used.[10] The network meta-analyses were conducted
16 using the “network” suite in Stata Version 14.0 (StataCorp LP, College Station, TX, USA).[10]
17
18
19
20
21
22
23
24
25

26 **Sensitivity Analysis**

27
28 We examined the effects of the drugs for CIC based on relative risks of the primary and
29 secondary endpoints. We evaluated effect sizes based on therapeutic dose (standard dose group
30 versus high dose) and study quality for prucalopride (low risk of bias versus high risk of bias) for
31 CIC treatment. We also applied the “leave-one-out” method by excluding one study of 24 weeks
32 duration to evaluate the robustness of our findings.
33
34
35
36
37
38
39
40

41 **Assessment of Risk of Bias and Publication Bias**

42
43 Risk of bias was assessed using Cochrane Handbook for Assessing the Risk of Bias [9].
44
45 Two investigators (AN and PV) independently assessed the randomization schedule, allocation
46 concealment, blinding of participants and investigators, blinding of outcome assessment,
47 methods used for missing data, selective reporting, incomplete outcome data, risk of bias for
48 primary and secondary endpoints, and loss of follow up during the treatment period. Due to the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 limited number of studies included in the analyses, we were not able to evaluate potential
4
5 publication bias.[11]
6
7

8 **Quality of Evidence**

9
10 We used the Grading of Recommendation, Assessment, Development and Evaluation
11 (GRADE) Approach to rate the quality of evidence for the estimates derived from the network
12 meta-analyses.[12] Since the studies included were only randomized, placebo-controlled trials,
13
14 the quality of evidence was considered high in the beginning and down rated based on the
15
16 assessment of risk of bias, inconsistency, indirectness, imprecision and publication bias. The
17
18 quality of evidence is rated as high, moderate, low and very low. For indirect estimates, the
19
20 rating usually starts at lowest rating of contributing direct evidence and can be further down
21
22 rated based on imprecision and indirectness (mainly intransitivity, i.e., difference in patient
23
24 populations between studies involved).
25
26
27
28
29
30

31 **RESULTS**

32 **Search Results**

33
34 The search strategy used identified 546 citations and, among these, we identified 114
35
36 articles for review for the full text appraisal. Among the 114 articles, only 18 articles met the
37
38 inclusion criteria; 96 studies did not meet the inclusion criteria, most often because the endpoints
39
40 in the trials were different from the selected primary and secondary endpoints, articles did not
41
42 have original data, or they were nonrandomized studies. The agreement between the
43
44 investigators (AN and NV) for selection of studies after full text review was high (Kappa statistic
45
46 0.86).
47
48
49
50
51

52
53 Three studies which were not identified by the search strategy were added by the
54
55 investigators. We contacted the authors and drug sponsors of these studies for additional
56
57
58
59
60

1
2
3 information regarding the primary and secondary endpoints, and their responses were added to
4
5 the analysis.
6

7
8 Figure 1 shows the schematic diagram of study selection for the systematic review and
9
10 meta-analysis; in total, 21 studies were eligible. The study characteristics are summarized in
11
12 Table 1.
13

14
15 There were 9189 patients in the 21 studies: 9 with prucalopride,[13, 14, 15, 16, 17, 18,
16
17 19, 20, 21] 3 with lubiprostone,[22, 23, 24] 3 with linaclotide,[25, 26, 27] 2 with tegaserod,[28,
18
19 29] 1 each with Velusetrag,[30] Elobixibat,[31] bisacodyl,[32] and sodium (Na)
20
21 picosulphate.[33] The number of drugs, sample size of each drug, and the number of clinical
22
23 trials included in the network meta-analysis are represented in the form of a network diagram
24
25 (Figure 2).
26
27

28
29 The risk of bias of the included studies is summarized in Table 2. Overall, quality was
30
31 high in 11, moderate in 9, and low in 1 study. Downgrading of quality was based most often on
32
33 unstated details regarding blinding, allocation concealment or management of missing data.
34
35

36 **Direct Meta-analysis**

37
38 The results of the direct meta-analysis for each primary and secondary endpoint are
39
40 summarized in Figure 3A-D.
41
42

43 *Primary Endpoints*

44
45 The data for responder analysis with ≥ 3 CSBM/week were available for 14 randomized,
46
47 placebo-controlled trials. All six drugs showed a significant increase in ≥ 3 CSBM/week when
48
49 compared to placebo. Among the three 5HT₄ agonists (prucalopride, velusetrag and tegaserod),
50
51 prucalopride showed higher efficacy [relative risk (RR)] of 1.85 with a 95% confidence interval
52
53 (CI) of 1.35 to 2.54 when compared to placebo and with significant heterogeneity of 80.8%
54
55
56
57
58
59
60

($p=0.0001$). Velusetrag had an RR of 4.86 (95% CI, 2.02 to 11.71); the wider confidence interval may suggest velusetrag might be less efficacious, ~~was considered inferior~~ when compared to prucalopride ~~since the CI is wide~~. Stimulant laxatives, bisacodyl and NaP, showed approximately similar efficacy. For linaclotide, RR was 1.96 (95% CI, 1.12 to 3.44). There was significant heterogeneity between studies of all the drugs appraised using this endpoint ($I^2 = 77.4\%$ $P < 0.00001$).

For responder analysis with increase over baseline by ≥ 1 CSBM/week, data were available for 15 randomized, placebo-controlled trials; all 7 of the drugs were superior to placebo. Stimulant laxatives (bisacodyl and NaP) and elobixibat showed approximately similar efficacy. Prucalopride showed superior efficacy among the 5HT₄ agonists, but the heterogeneity between studies was significant ($I^2 = 74.5\%$, $p=0.0001$). Even though the RR for velusetrag was 3.10, which is relatively high when compared to the RR for prucalopride, the 95% CI with velusetrag was wide (1.83 to 5.24) and overlapped that of prucalopride. Given the overlapping 95% CI for the two drugs and the significant heterogeneity in the efficacy of prucalopride, the data show overall similar efficacy for prucalopride and velusetrag.

Secondary Endpoints

Data for Δ_b CSBM/week were available only for 5 drugs. All the drugs showed superior efficacy when compared to placebo. Bisacodyl had a weighted mean difference (WMD) of 3.20 (95% CI, 2.66 to 3.74). Elobixibat and NaP had similar efficacy. For linaclotide, the WMD was 1.57, with heterogeneity I^2 of 0%; this WMD was greater than that of prucalopride which was 0.90 and was also associated with significant heterogeneity I^2 of 76.8%.

For the Δ_b SBM/week, all 7 of the drugs showed superior efficacy relative to placebo. Bisacodyl showed higher efficacy with a WMD of 4.90 when compared to NaP (3.20).

1
2
3 Velusetrag, elobixibat and linaclotide showed similar efficacy with a mean difference (MD) in
4
5 the absolute number of Δ_b SBM/week of ~ 2.08 . For prucalopride, the WMD was 2.03, with
6
7 significant heterogeneity of 63.9%. For lubiprostone, WMD was 1.91 with an I^2 of 23.4%.
8
9

10 Network Meta-analysis

11 Responder analysis for ≥ 3 CSBM/week (Table 3A)

12
13 Except for tegaserod, all the other drugs (bisacodyl, NaP, prucalopride, velusetrag,
14
15 linaclotide and elobixibat) showed superior efficacy compared to placebo, but none of the drugs
16
17 showed superior efficacy when compared to each other in the network meta-analysis.
18
19

20 Responder analysis for increase over baseline by ≥ 1 CSBM/week (Table 3B)

21
22 Apart from tegaserod and linaclotide, all the drugs (bisacodyl, NaP, prucalopride and
23
24 velusetrag) showed superior efficacy when compared to placebo, but none of the drugs showed
25
26 superior efficacy when compared to each other in the network meta-analysis, with the exception
27
28 of velusetrag which appears superior when compared to prucalopride and tegaserod.
29
30
31

32 Change in number of CSBM/week compared to baseline (Table 4A)

33
34 Bisacodyl, NaP, prucalopride, linaclotide and elobixibat showed superior efficacy on the
35
36 Δ_b CSBM/week when compared to placebo. On a network meta-analysis, bisacodyl was superior
37
38 to NaP, prucalopride and linaclotide. Bisacodyl did not show significant efficacy over elobixibat
39
40 using this endpoint. NaP showed superior efficacy when compared to prucalopride.
41
42
43

44 Change in number of SBM/week compared to baseline (Table 4B)

45
46 When compared to placebo on a network meta-analysis, bisacodyl, NaP, prucalopride,
47
48 velusetrag, linaclotide, elobixibat and lubiprostone treatment showed superior increase in
49
50 Δ_b SBM/week.
51
52
53
54
55
56
57
58
59
60

1
2
3 Network meta-analysis suggested that bisacodyl is superior when NaP, prucalopride,
4 velusetrag, linaclotide, elobixibat and lubiprostone are compared to bisacodyl. NaP showed
5 superior efficacy when prucalopride and lubiprostone were compared to NaP.
6
7
8
9

10 **Quality of Evidence**

11 We applied the GRADE approach to the main outcome of ≥ 1 CSBM/week because it had
12 the largest number of included trials. In terms of direct estimates of drugs compared to placebo,
13 the quality of evidence was moderate or high for all comparisons. However, most head-to-head
14 comparisons were imprecise (i.e., their CIs were wide and overlapped the null effect). Therefore,
15 the quality of evidence of head-to-head comparisons was mostly low (Table 5).
16
17
18
19
20
21
22
23

24 **Sensitivity Analysis**

25 We conducted sensitivity analyses based on dose of medication (for all drugs for which at
26 least two doses were studied) and risk of bias (for prucalopride). Results were consistent between
27 standard therapeutic dose group compared to high and low dose groups for the primary endpoints
28 and for most of the secondary endpoint analyses (Table 6). An exception was that low dose (in
29 contrast to standard or high dose) prucalopride was not effective compared to placebo for the
30 endpoints of ≥ 3 CSBM/week and Δb SBM/week.
31
32
33
34
35
36
37
38
39
40

41 When analysis was restricted to prucalopride studies at low risk of bias, four trials [13, 16,
42 18, 19] were included and, for the two primary responder analyses, we noted that for
43 ≥ 3 CSBM/week, the RR was 2.12 (1.71, 2.63) and, for increase over baseline by ≥ 1
44 CSBM/week, the RR was 1.76 (1.54, 2.02); both had heterogeneity of 0%.
45
46
47
48
49

50 A third sensitivity analysis assessed whether any one study with a markedly different
51 duration [17] had a dominant effect on the pooled RR or heterogeneity. We found that this single
52 study did not markedly affect the summary estimate for the prucalopride studies. Thus, including
53
54
55
56
57
58
59
60

1
2
3 the study resulted in RRs for ≥ 3 CSBM/week and for increase over baseline by ≥ 1 CSBM/week
4
5 of 1.85 (I^2 80.8%) and 1.54 (I^2 74.3%), respectively; excluding the study, the RRs were 1.96 (I^2
6
7 81.8%) and 1.63 (I^2 66.4%), respectively.
8
9

10 DISCUSSION

11
12 Our study has shown that each drug used in the treatment of CIC is superior to placebo,
13
14 based on the published randomized, placebo-controlled trials. All the drugs are equally
15
16 efficacious for the primary endpoints of responder analysis with ≥ 3 CSBM/week and increase
17
18 over baseline by ≥ 1 CSBM/week, in the network meta-analysis. Bisacodyl may be superior to all
19
20 the other drugs in the secondary endpoint of Δ_b SBM/week and in comparison with some of the
21
22 drugs in Δ_b CSBM/week.
23
24
25
26

27 There are, however, limitations in this appraisal of relatively greater efficacy of
28
29 bisacodyl. There is only one bisacodyl trial with only 4 weeks of treatment compared to other
30
31 drugs which provided treatment for 12 or 24 weeks. Confirmation of superiority of any of these
32
33 pharmacotherapies requires direct comparisons of the active interventions using randomized,
34
35 placebo-controlled trials. A network meta-analysis has distinct features in the absence of trials of
36
37 direct comparisons of treatments, and may inform judicious selection of treatment. The
38
39 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recommends use
40
41 of multiple treatment meta-analyses in synthesis of data, even with nodal networks, as it allows
42
43 for more statistically sound assessment of comparative efficacy.[34]
44
45
46
47

48 Typically, patients in these randomized, placebo-controlled trials fulfilled Rome II or III
49
50 criteria for constipation after exclusion of medical and structural conditions.[35] These
51
52 symptom-based criteria do not differentiate groups, based on the pathophysiology causing CIC.
53
54
55 Based on a study of symptoms and pathophysiology in 1411 patients, subgroups of CIC were
56
57
58
59
60

1
2
3 identified, based on pathophysiology: normal transit constipation (NTC) in ~70%, dyssynergic
4 defecation in ~25%, and slow transit constipation (STC) in ~4.5%. [36] In fact, epidemiological
5 studies also have shown that about one-third of people in the community who experience
6 constipation endorse symptoms consistent with dyssynergic defecation.[4] With a preponderance
7 of CIC patients being female and having NTC, the similar efficacy to all the classes of drugs for
8 the treatment of CIC is not surprising.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Prior randomized, placebo-controlled trials included in this analysis did not subgroup patients according to pathophysiology; hence, we are unable to report efficacy in subgroups of CIC. It is conceivable that patients with STC might respond better to treatment with agents that have significant effects on colonic motor function. Several of the agents evaluated in this network meta-analysis accelerate colonic transit, including intestinal secretagogues (lubiprostone,[37] linaclotide,[38] and the bile acid transport inhibitor, elobixibat [39]) and prokinetic agents (prucalopride,[40] tegaserod,[41] and bisacodyl [42]). However, among all these drugs, only prucalopride [43] and bisacodyl have been shown to increase the number of high amplitude propagated contractions (HAPC), which are highly propulsive in the colon.[44] Lubiprostone did not induce colonic high amplitude contractions.[45]

A recent consensus monograph, based on meta-analysis of treatments of CIC, gave strong recommendation for treatment with fiber, osmotic laxatives (PEG, lactulose), stimulant laxatives (NaP and bisacodyl), prucalopride, linaclotide and lubiprostone.[46] However, the quality of evidence was considered moderate in some of the trials, there were no direct comparisons between active drugs, and the analysis used as primary endpoint the failure to respond to therapy. This appraisal actually combined in non-responder status failure to respond to different endpoints in each trial. In addition, the secondary endpoints evaluated did not differentiate SBM from

1
2
3 CSBM. Despite these methodological differences, our direct and network meta-analyses confirm
4
5 the general conclusion of the prior report regarding the efficacy of each intervention relative to
6
7 placebo with reference to the primary endpoints (which are the components of the endpoint
8
9 currently recommended by FDA), although there is a possible difference in efficacy on
10
11 secondary endpoints between bisacodyl and other drugs.
12
13

14
15 Our study has some limitations. There is only one randomized, placebo-controlled trial
16
17 for 4 of the drugs included in the meta-analysis (NaP, bisacodyl, velusetrag and elobixibat), and
18
19 osmotic laxatives such as PEG, lactulose, and magnesium salts were not included, since the
20
21 endpoints in those studies were not uniform or consistent with the inclusion criteria. This
22
23 particularly applies to the trials with PEG.[47, 48, 49, 50] There is one randomized, placebo-
24
25 controlled trial directly comparing PEG3350 + electrolytes (PEG3350+E) to prucalopride
26
27 treatment,[51] but this was a single-center study conducted in a controlled environment on
28
29 patients many of whom had features suggesting evacuation disorder at baseline: ~50% reported
30
31 sensation of anal blockage and 15% manual maneuvers to facilitate defecation. Moreover, the
32
33 primary endpoint was the proportion of patients having ≥ 3 SCBMs during the last week of
34
35 treatment in a 4-week trial, rather than the entire treatment period, and the randomized, placebo-
36
37 controlled trial showed non-inferiority of PEG3350 + E to prucalopride, consistent with our
38
39 general conclusion that the approved pharmacotherapies for CIC have similar efficacy.
40
41
42
43
44

45
46 Other limitations in our network meta-analysis are the variability in the duration of
47
48 treatment (4 to 24 weeks) and safety and adverse events for the drugs were not analyzed in our
49
50 study. Another limitation is that, in many of these pivotal clinical trials, bisacodyl is often used
51
52 as the rescue medication, and the impact of this on the “placebo” arms could not be appraised as
53
54 it is not reported in detail in the trials. It is also conceivable that the high number of prucalopride
55
56
57
58
59
60

1
2
3
4 trials impacted the relative assessment of efficacy by reducing the width of the confidence
5
6 interval of the RR; therefore, we have interpreted cautiously the RR differences between
7
8 prucalopride and velusetrag which was the only medication identified as less efficacious than
9
10 prucalopride in the statistical analysis.

11
12
13 Strengths in our study design and network meta-analysis include trials with similar
14 patient population, comparators, outcome assessments, and trial design; application of the
15 GRADE approach to provide an objective and transparent assessment of the quality of evidence
16 for evaluating comparative efficacy of these agents;[52] and the inclusion of the responder
17 analyses as well as secondary endpoints which are very relevant in view of differences in
18 baseline SBM and CSBM between studies.[53]

19
20
21
22
23
24
25
26
27 In conclusion, network meta-analysis shows that current pharmacotherapies for CIC have
28 similar efficacy. Based on secondary endpoints, bisacodyl may be superior to other medications
29 prescribed for CIC; however, bisacodyl is associated with abdominal cramps and diarrhea. In the
30
31
32
33
34 future, head-to-head trials of active agents are necessary to determine the efficacy and adverse
35
36 effects in order to facilitate optimal selection of pharmacological agents for CIC instead of the
37
38
39 current choice based on failure of prior drugs.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Acknowledgements:** We thank Dr. Fabio Cataldi and Dr. Debra Silberg (Shire Pharmaceuticals,
5 Turnhout, Belgium), [the late](#) Dr. Hans Graffner (Albireo, Göteborg, Sweden), Dr. Sabine
6 Niedermeier (Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany), Dr. Peter
7 Lichtlen (Sucampo AG, Bethesda, MD), Dr. Fukudo Shin (Tohoku University, Sendai, Japan),
8 Dr. Michael A Kamm (University of Melbourne, Melbourne, Australia) and Dr. Stefan Mueller-
9 Lissner (Lehrkrankenhaus der Charité, Universitätsmedizin, Berlin, Germany) for providing
10 access to clinical trial data for medications reviewed in this article.
11

12
13 **Funding:** Dr. Camilleri is supported by grant R01-DK92179 from National Institutes of Health
14 for studies on lower functional gastrointestinal disorders.
15

16
17 **Competing Interests:** Dr. Camilleri received grants for research on pharmacodynamics of
18 prucalopride, velusetrag, elobixibat, linaclotide, and lubiprostone in the past decade. Dr.
19 Camilleri serves as an advisor to Albireo, Rhythm, and Theravance, with compensation for his
20 time serving as an advisor paid to his employer, Mayo Clinic, not to himself personally.

21 [The other authors have no competing interests.](#)
22

23
24 **Authors' contributions:**

25 Alfred D. Nelson: concept development, data analysis, selection of articles, authorship
26 Michael Camilleri: concept development, data analysis, selection of articles, authorship
27 Sakkarin Chirapongsathorn: network meta-analysis, authorship
28 Priya Vijayvargiya: assessment of study quality, authorship
29 Nelson Valentin: selection of articles to be included after the literature search, authorship
30 Andrea Shin: analysis of data on 5HT₄ agonists, authorship
31 Patricia J. Erwin: literature search for systematic review, authorship
32 Zhen Wang: network meta-analysis, authorship
33 M. Hassan Murad: systematic review and network meta-analysis, authorship
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 Suarez NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation
2 in the community: systematic review and meta-analysis. *Am J Gastroenterol* 2011;106:1582-91;
3 quiz 1, 92.
- 4 Longstreth GF, Thompson WG, Chey WD, et al. Functional Bowel Disorders.
5 *Gastroenterology* 2006;130:1480-91.
- 6 Peery AF, Crockett SD, Barritt AS, et al. Burden of Gastrointestinal, Liver, and
7 Pancreatic Diseases in the United States. *Gastroenterology* 2015;149:1731-41.e3.
- 8 Bharucha AE, Pemberton JH, Locke III GR. American Gastroenterological Association
9 Technical Review on Constipation. *Gastroenterology* 2013;144:218-38.
- 10 Voderholzer WA, Schatke W, Muhldorfer BE, et al. Clinical response to dietary fiber
11 treatment of chronic constipation. *Am J Gastroenterol* 1997;92:95-8.
- 12 Ford AC, Suarez NC. Effect of laxatives and pharmacological therapies in chronic
13 idiopathic constipation: systematic review and meta-analysis. *Gut* 2011;60:209-18.
14 [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
15 2014/02/WC500162134.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162134.pdf)
- 16 Higgins JP, Strene JAC. *Cochrane Handbook for Systematic Reviews of interventions* In:
17 Higgins JP and Green S ed. Available from www.cochrane-handbook.org.: The Cochrane
18 Collaboration; 2011.
- 19 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for
20 Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care
21 Interventions: Checklist and Explanations PRISMA Extension for Network Meta-analysis.
22 *Annals of Internal Medicine* 2015;162:777-84.
- 23 White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-
24 analysis: model estimation using multivariate meta-regression. *Research Synthesis Methods*
25 2012;3:111-25.
- 26 Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias
27 in meta-analyses: a large survey. *CMAJ* 2007;176:1091-6.
- 28 Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating
29 of confidence in effect estimates for a single outcome and for all outcomes. *Journal of Clinical
30 Epidemiology* 2013;66:151-7.
- 31 Camilleri M, Kerstens R, Rykx A, et al. A Placebo-Controlled Trial of Prucalopride for
32 Severe Chronic Constipation. *New England Journal of Medicine* 2008;358:2344-54.
- 33 Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with
34 severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a
35 double-blind, placebo-controlled clinical trial. *Digestion* 2003;67:82-9.
- 36 Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in
37 patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study.
38 *Neurogastroenterology & Motility* 2012;24:999-e541.
- 39 Müller-lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of
40 prucalopride in elderly patients with chronic constipation. *Neurogastroenterology & Motility*
41 2010;22:991-e255.
- 42 Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled
43 trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride.
44 *Neurogastroenterology & Motility* 2015;27:805-15.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 18 Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. *Alimentary Pharmacology & Therapeutics* 2009;29:315-28.
- 19 Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. *Gut* 2009;58:357-65.
- 20 Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. *Alimentary Pharmacology & Therapeutics* 2002;16:1347-56.
- 21 Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation. *Am J Gastroenterol* 2015;110:741-8.
- 22 Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Lubiprostone, a Locally-Acting Type-2 Chloride Channel Activator, in Patients With Chronic Constipation. *Am J Gastroenterol* 2008;103:170-7.
- 23 Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. *Dig Dis Sci* 2010;55:1090-7.
- 24 Fukudo S, Hongo M, Kaneko H, et al. Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation. *Clinical Gastroenterology and Hepatology* 2015;13:294-301.e5.
- 25 Lacy BE, Schey R, Shiff SJ, et al. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial. *PLoS ONE* 2015;10:e0134349.
- 26 Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of Linaclotide for Patients With Chronic Constipation. *Gastroenterology* 2010;138:886-95.e1.
- 27 Lembo AJ, Schneier HA, Shiff SJ, et al. Two Randomized Trials of Linaclotide for Chronic Constipation. *New England Journal of Medicine* 2011;365:527-36.
- 28 Fried M, Johanson JF, Gwee KA, et al. Efficacy of Tegaserod in Chronic Constipation in Men. *Am J Gastroenterol* 2007;102:362-70.
- 29 Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the Treatment of Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Multinational Study. *Am J Gastroenterol* 2005;100:362-72.
- 30 Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4-week, randomized, double-blind, placebo-controlled, dose–response study. *Alimentary Pharmacology & Therapeutics* 2010;32:1102-12.
- 31 Chey WD, Camilleri M, Chang L, et al. A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. *Am J Gastroenterol* 2011;106:1803-12.
- 32 Kamm MA, Mueller-Lissner S, Wald A, et al. Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation. *Clinical Gastroenterology and Hepatology* 2011;9:577-83.
- 33 Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients With Chronic Constipation. *Am J Gastroenterol* 2010;105:897-903.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 34 Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value Health* 2011;14:429-37.
- 35 Locke III GR, Pemberton JH, Phillips SF. AGA technical review on constipation. *Gastroenterology* 2000;119:1766-78.
- 36 Nullens S, Nelsen T, Camilleri M, et al. Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. *Gut* 2012;61:1132-9.
- 37 Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2006;290:G942-G7.
- 38 Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 Days Linaclotide on Transit and Bowel Function in Females With Constipation-Predominant Irritable Bowel Syndrome. *Gastroenterology* 2007;133:761-8.
- 39 Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional Constipation. *Am J Gastroenterol* 2011;106:2154-64.
- 40 Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. *Gastroenterology* 2001;120:354-60.
- 41 Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. *Gastroenterology* 2000;118:463-8.
- 42 Manabe N, Cremonini F, Camilleri M, et al. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. *Alimentary Pharmacology & Therapeutics* 2009;30:930-6.
- 43 Miner P, Camilleri M, Burton D, et al. Prucalopride induces high amplitude propagated contractions in the colon of patients with chronic constipation: A randomized study. *Neurogastroenterology and Motility* 2015;27:86-.
- 44 Preston DM, Lennard-Jones JE. Pelvic motility and response to intraluminal bisacodyl in slow-transit constipation. *Dig Dis Sci* 1985;30:289-94.
- 45 Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2009;296:G295-G301.
- 46 Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. *Am J Gastroenterol* 2014;109:S2-S26.
- 47 DiPalma JA, Cleveland MB, McGowan J, et al. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. *South Med J* 2007;100:1085-90.
- 48 DiPalma JA, Cleveland Mv, McGowan J, et al. A Randomized, Multicenter, Placebo-Controlled Trial of Polyethylene Glycol Laxative for Chronic Treatment of Chronic Constipation. *Am J Gastroenterol* 2007;102:1436-41.
- 49 Corazzari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. *Gut* 2000;46:522-6.

1
2
3 50 Corazziari E, Badiali D, Habib FI, et al.. Small volume isosmotic polyethylene glycol
4 electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. *Dig*
5 *Dis Sci* 1996;41:1636-42.

6
7 51 Cinca R, Chera D, Gruss HJ, et al. Randomised clinical trial: macrogol/PEG
8 3350+electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in
9 a controlled environment. *Alimentary Pharmacology & Therapeutics* 2013;37:876-86.

10 52 Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for
11 rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;349.

12 53 Bielefeldt K, Levinthal DJ, Nusrat S. Effective Constipation Treatment Changes More
13 Than Bowel Frequency: A Systematic Review and Meta-Analysis. *Journal of*
14 *Neurogastroenterology and Motility* 2016;22:31-45.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Study Characteristics

Study ID	Location	Drug	Doses tested	Study Duration (weeks)	Number Total: Intervention/control	Age (I)	Age (C)	Gender, F %	Constipation criteria
Camilleri 2008	USA	PRU	2mg, 4 mg QD	12	620: 411/209	48.0±14.3	48.9±13.0	87.1	≤2 CSBM/week for 6 months, and Rome III criteria#
Coremans 2003	Belgium	PRU	4 mg QD	4	53: 27/26	43.8±2.7	47.4±2.9	98.1	≥2 of the following for 6 months: 2 SBM/week and Rome III criteria#
Ke 2012	Asia-pacific	PRU	2mg QD	12	501: 249/252	41.4±12.9 2	41.8±12.9	90	≤2 SBM/week on average, and ≥1 of the following in Rome III criteria*
Mueller-Lissner 2010	Int	PRU	1mg, 2mg, 4 mg QD	4	300: 230/70	76.5±7.7	76±7.4	70.3	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria#
Piessevaux 2015	Europe	PRU	2mg QD	24	346: 177/169	49.4±15.8	48.3±16.3	14.7 ^s	≤2 CSBM/week and ≥1 of the following in Rome III criteria# for 6 months
Quigley 2009	USA	PRU	2mg, 4 mg QD	12	641: 429/212	48.9±13.9	46.2±13.0	86.6	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria# for 6 months
Tack 2009	Int	PRU	2mg, 4 mg QD	12	713: 473/240	44.1±15.1	43.7±15.3	90.8	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria# for 6 months
Emmanuel 2002	UK	PRU	1mg QD	4	74: 37/37	NA	NA	100	≤2 SBM/week and need to strain at least 25% of the defecation.
Yiannakou 2015	Europe	PRU	2mg QD	12	370: 184/186	58.4±17.6	58.5±16.3	0 ^f	≤2 CSBM/week for 6 months and ≥1 of the following in Rome III criteria# for 6 months
Goldberg 2010	USA	VEL	15mg, 30mg, 45mg QD	4	401: 294/107	44.4±11.7	45.4±10.0	92.0	≥18 years of age satisfying Rome 3 criteria functional constipation*
Fried 2007	Int	TEG	6mg bid	12	322: 158/164	51.1±17.1	51.8±17.2	0 ^f	≤3 CSBM/week and ≥1 of the following in Rome III criteria# for 6 months
Kamm 2005	Int	TEG	2mg, 6mg bid	12	1264: 848/416	46.3±15.2	46.0±15.6	86.3	≤3 CSBM/week and ≥1 of the following in Rome III criteria# for 6 months

Barish 2010	USA	LUBI	24mcg bid	4	237: 119/118	NK	NK	88.2	≤3 SBM/week and ≥1 of the following in Rome III criteria [#] for 6 months
Fukudo 2015	Japan	LUBI	24mcg bid	4	124: 62/62	42.7±16.4	41.5±14.2	88	Rome III criteria*, fewer than 3 defecations per week.
Johanson 2008	USA	LUBI	24mcg bid	4	244: 120/124	48.0±12.3	49.1±12.9	89.7	≤3 SBM/week and ≥1 of the following in Rome III criteria [#] for 6 months
Chey 2011	USA	ELO	5, 10, or 15mgQD	4	190: 143/47	47.6	49.9	89.5	<3 CSBM/week and ≥2 of the following in Rome III criteria*
Kamm 2011	UK	BIS	10mg QD	4	356: 239/117	55.8±15.9	54.7±15.1	74.7	< 3 CSBM/week and ≥1 of the following in Rome III criteria [#] for 6 months
Mueller-lissner 2010	Germany	NaP	10mg QD	4	362: 229/133	50.2±17.2	51.9±16.5	77.7	< 3 CSBM/week on average and ≥1 of the following in Rome III criteria [#] for 6 months
Lembo 2010	USA	LINA	75, 150, 300, or 600mcg QD	4	307: 239/68	47.6±13.1	46.1±15.6	92	<3 SBM/week and ≥1 of the following in Rome III criteria [#] at least 12 weeks during the 12 months preceding the study
Lembo 2011	USA	LINA	145 or, 290mcg, QD	12	643: 434/209	47.4±14.2	49.3±14.3	87.4	< 3 SBM/week and ≥1 of the following Rome criteria [#] for at least 12 weeks within the preceding 12 months
		LINA		12	633: 418/215	47.2±12.8	47.0±13.5	90.4	
Lacy 2015	USA	LINA	145 or, 290mcg, QD	12	487: 314/173	47.9	46.4	92.5	< 3 SBM/week and ≥1 of the following Rome criteria [#] for at least 12 weeks within the preceding 12 months

*- Rome III criteria which includes straining,

[#] - Part of the Rome III criteria which includes ≥25% straining, incomplete evacuation and hard/lumpy stools,

^{\$} - 85.32% were male, [¶] 100% were men,

PRU- Prucalopride, VEL- Velusetrag, TEG- Tegaserod, LUBI- Lubiprostone, ELO- Elobixibat, BIS- Bisacodyl, NaP- Sodium Picosulphate, LINA- Linaclotide, MC- Multicenter, SC- Single center, Int- International, I- Intervention, C- Control.

Table 2. Study Quality (CGR=computer generated randomization; Rx=intervention arm, C=control; LOCF=last observation carried forward; PRU=prucalopride, VEL=velusetrag, TEG=tegaserod, LUBI=lubiprostone, ELO=elobixibat, BIS=bisacodyl, NaP=sodium picosulphate, LINA=linaclotide)

Study Identification	Drug	Generation of randomization sequence	Allocation concealment	Double Blind	Lost to follow up	Methods used for missing data	Overall Quality
Camilleri 2008	PRU	Consecutive numbering + block randomization of 3	+	+	5Rx, 3C	Imputation	High
Coremans 2003	PRU	Unclear	Unclear	+	0	-	Mod
Ke 2012	PRU	CGR	+	+	3Rx, 2C	NS	Mod
Mueller-Lissner 2010	PRU	Randomization code generated by sponsor	+	+	0	Considered as non-responders	High
Piessevaux 2015	PRU	Randomization by web-based/voice-response system.	+	+	0	Imputation	Low
Quigley 2009	PRU	Block randomization of three	+	+	5Rx, 2C	Imputation	High
Tack 2009	PRU	Random allocation sequence by the investigator	Unclear	+	5Rx, 1C	Considered as non-responders	High
Emmanuel 2002	PRU	Method not known	Unclear	+	0Rx, 1C	NS	Mod
Yiannakou 2015	PRU	Central interactive web based response system	+	+	2Rx, 0C	Imputation	Mod
Goldberg 2010	VEL	Telephonic interactive voice response system using a permuted block algorithm	+	+	NK	LOCF	High
Fried 2007	TEG	Validated system that automated the random assignment by sponsor	+	+	0	-	High
Kamm 2005	TEG	Randomized using validated computer system	+	+	26Rx, 10C	NS	Mod
Barish 2010	LUBI	Block randomization of four	+	+	4Rx, 1C	LOCF	Mod
Fukudo 2015	LUBI	Method not known	Unclear	+	0	-	Mod
Johanson 2008	LUBI	Block randomization of four	+	+	1Rx, 2C	LOCF	Mod
Chey 2011	ELO	CGR by sponsor	+	+	1Rx, 0C	NS	Mod
Kamm 2011	BIS	CGR	+	+	0	-	High
Mueller-Lissner 2010	NaP	CGR	+	+	0	-	High
Lembo 2010	LINA	CGR using a block size of 5	+	+	3Rx, 0C	Observed-cases approach	Mod
Lembo 2011	LINA	CGR using a block size of 6	+	+	29Rx, 4C		High
Lacy 2015	LINA	Randomization by statistical programmer not involved in the trial	+	+	10Rx, 5C	Considered as non-responders	High

Table 3. Pooled RR, and 95% confidence intervals (for network meta-analysis) for primary endpoints (p<0.05 is bolded). (Note: For lubiprostone, both of the endpoints are not available +=Superior, -=Inferior).

3A. Responders with ≥ 3 CSBM per week for the drugs for CIC

Responders with ≥ 3 CSBM/week						
<i>Placebo</i>	2.46 (1.14, 5.31)	2.83 (1.27, 6.31)	1.84 (1.40, 2.43)	1.47 (0.7, 3.12)	4.86 (1.58, 14.99)	1.96 (0.8, 4.81)
	<i>Bisacodyl</i>	1.15 (0.38, 3.49)	0.75 (0.33, 1.69)	0.59 (0.20, 1.75)	1.97 (0.51, 7.72)	0.79 (0.24, 2.60)
		<i>Sodium picosulphate</i>	0.65 (0.28, 1.52)	0.52 (0.17, 1.56)	1.72 (0.43, 6.84)	0.69 (0.21, 2.31)
			<i>Prucalopride</i>	0.80 (0.36, 1.78)	2.64 (0.83, 8.41)	1.06 (0.41, 2.72)
				<i>Tegaserod</i>	3.30 (0.85, 12.79)	1.33 (0.41, 4.30)
					<i>Velusetrag</i>	0.40 (0.09, 1.70)
						<i>Linacotide</i>

3B. Responders with ≥ 1 CSBM per week for the drugs for CIC

Responders with <u>increase over baseline by</u> ≥ 1 CSBM/week							
<i>Placebo</i>	2.04 (1.3, 3.19)	2.03 (1.27, 3.23)	1.54 (1.30, 1.83)	1.33 (0.97, 1.83)	3.1 (1.61, 5.95)	1.72 (1.0, 2.96)	1.97 (1.09, 3.55)
	<i>Bisacodyl</i>	0.99 (0.52, 1.9)	0.76 (0.47, 1.22)	0.65 (0.38, 1.13)	1.52 (0.69, 3.35)	0.84 (0.42, 1.71)	0.96 (0.46, 2.02)
		<i>Sodium picosulphate</i>	0.76 (0.46, 1.25)	0.66 (0.37, 1.16)	1.53 (0.69, 3.41)	0.85 (0.42, 1.74)	0.97 (0.46, 2.06)
			<i>Prucalopride</i>	0.86 (0.60, 1.23)	2.01 (1.02, 3.93)	1.11 (0.63, 1.97)	1.27 (0.69, 2.35)
				<i>Tegaserod</i>	2.33 (1.13, 4.80)	1.29 (0.69, 2.42)	1.48 (0.76, 2.89)
					<i>Velusetrag</i>	0.56 (0.24, 1.30)	0.64 (0.26, 1.53)
						<i>Linacotide</i>	1.14 (0.51, 2.55)
							<i>Elobixibat</i>

Table 4. Pooled weighted mean difference, and 95% confidence intervals (for network meta-analysis) for Secondary endpoints (p<0.05 is bolded). (Note: Tegaserod both of the endpoints are not available, +=Superior, -=Inferior).

4A. Number of CSBM change from baseline for the drugs for CIC

# of CSBM/week change from baseline					
<i>Placebo</i>	3.2 (2.37, 4.03)	2.0 (1.19, 2.81)	0.9 (0.52, 1.28)	1.55 (0.90, 2.19)	1.99 (0.77, 3.22)
	<i>Bisacodyl</i>	-1.2 (-2.36, -0.04)	-2.3 (-3.22, -1.38)	-1.65 (-2.70, -0.60)	-1.21 (-2.69, -0.28)
		<i>Sodium picosulphate</i>	-1.10 (-1.99, -0.21)	-0.45 (-1.48, 0.58)	-0.01 (-1.47, 1.46)
			<i>Prucalopride</i>	0.65 (-0.10, 1.40)	1.09 (-0.19, 2.38)
				<i>Linaclotide</i>	0.44 (-0.94, 1.83)
					<i>Elobixibat</i>

4B. Number of SBM change from baseline for the drugs for CIC

# of SBM/week change from baseline							
<i>Placebo</i>	4.9 (3.90, 5.90)	3.20 (2.28, 4.12)	1.93 (1.45, 2.40)	2.07 (1.12, 3.01)	2.13 (1.54, 2.71)	2.08 (0.76, 3.41)	1.93 (1.30- 2.55)
	<i>Bisacodyl</i>	-1.7 (-3.05, -0.35)	-2.97 (-4.07, -1.87)	-2.83 (-4.20, -1.46)	-2.77 (-3.93, -1.62)	-2.82 (-4.48, -1.16)	-2.97 (-4.14- -1.79)
		<i>Sodium picosulphate</i>	-1.27 (-2.30, -0.24)	-1.13 (-2.45, 0.18)	-1.07 (-2.16, 0.01)	-1.12 (-2.73, 0.49)	-1.27 (-2.38- -0.16)
			<i>Prucalopride</i>	0.14 (-0.92, 1.20)	0.2 (-0.55, 0.95)	0.15 (-1.26, 1.56)	0 (-0.79- 0.79)
				<i>Velusetrag</i>	0.06 (-1.05, 1.17)	0.01 (-1.61, 1.64)	-0.14 (-1.27- 0.99)
					<i>Linaclotide</i>	-0.04 (-1.49, 1.40)	-0.2 (-1.05- 0.66)
						<i>Elobixibat</i>	-0.15 (-1.62- 1.31)
							<i>Lubiprostone</i>

Table 5. Quality of Evidence for Responders with ≥ 1 CSBM

(# -Inconsistency, ## -Severe inconsistency, \$ -Indirectness, \$\$ -Severe indirectness, * - Imprecision, ** - Severe imprecision, § -Risk of bias, p<0.05 is bolded)

Comparison	Direct	Quality of evidence	Indirect	Quality of evidence	Network	Quality of evidence
Bisacodyl v Placebo	2.04 (1.62, 2.57)	High	-	-	2.04 (1.3, 3.19)	High
Na P v Placebo	2.03 (1.56, 2.64)	High	-	-	2.03 (1.27, 3.23)	High
Prucalopride v Placebo	1.54 (1.28, 1.86)	Moderate [§]	-	-	1.54 (1.30, 1.83)	Moderate [§]
Tegaserod v Placebo	1.32 (1.14, 1.52)	High	-	-	1.33 (0.97, 1.83)	High
Velusetrag v Placebo	3.1 (1.83, 5.24)	High	-	-	3.1 (1.61, 5.95)	High
Linacotide v Placebo	1.72 (1.18, 2.52)	High	-	-	1.72 (1.0, 2.96)	High
Elobixibat v Placebo	1.97 (1.26, 3.07)	Moderate [§]	-	-	1.97 (1.09, 3.55)	Moderate [§]
Na P v Bisacodyl	-	-	0.99 (0.52, 1.9)	High	0.99 (0.52, 1.9)	Low**
Prucalopride v Bisacodyl	-	-	0.76 (0.47, 1.22)	Moderate	0.76 (0.47, 1.22)	Very Low**
Tegaserod v Bisacodyl	-	-	0.65 (0.38, 1.13)	High	0.65 (0.38, 1.13)	Low**
Velusetrag v Bisacodyl	-	-	1.52 (0.69, 3.35)	High	1.52 (0.69, 3.35)	Low**
Linacotide v Bisacodyl	-	-	0.84 (0.42, 1.71)	High	0.84 (0.42, 1.71)	Low**
Elobixibat v Bisacodyl	-	-	0.96 (0.46, 2.02)	Moderate	0.96 (0.46, 2.02)	Very Low**
Prucalopride v Na P	-	-	0.76 (0.46, 1.25)	Moderate	0.76 (0.46, 1.25)	Very Low**
Tegaserod v Na P	-	-	0.66 (0.37, 1.16)	High	0.66 (0.37, 1.16)	Low**
Velusetrag v Na P	-	-	1.53 (0.69, 3.41)	High	1.53 (0.69, 3.41)	Low**
Linacotide v Na P	-	-	0.85 (0.42, 1.74)	High	0.85 (0.42, 1.74)	Low**
Elobixibat v Na P	-	-	0.97 (0.46, 2.06)	Moderate	0.97 (0.46, 2.06)	Very Low**
Tegaserod v Prucalopride	-	-	0.86 (0.60, 1.23)	Moderate	0.86 (0.60, 1.23)	Very Low**
Velusetrag v Prucalopride	-	-	2.01 (1.02, 3.93)	Moderate	2.01 (1.02, 3.93)	Low*
Linacotide v Prucalopride	-	-	1.11 (0.63, 1.97)	Moderate	1.11 (0.63, 1.97)	Very Low**
Elobixibat v Prucalopride	-	-	1.27 (0.69, 2.35)	Moderate	1.27 (0.69, 2.35)	Very Low**
Velusetrag v Tegaserod	-	-	2.33 (1.13, 4.80)	High	2.33 (1.13, 4.80)	Moderate*
Linacotide v Tegaserod	-	-	1.29 (0.69, 2.42)	High	1.29 (0.69, 2.42)	Low**
Elobixibat v Tegaserod	-	-	1.48 (0.76, 2.89)	Moderate	1.48 (0.76, 2.89)	Very Low**
Linacotide v Velusetrag	-	-	0.56 (0.24, 1.30)	High	0.56 (0.24, 1.30)	Low**
Elobixibat v Velusetrag	-	-	0.64 (0.26, 1.53)	Moderate	0.64 (0.26, 1.53)	Very Low**
Elobixibat v Linacotide	-	-	1.14 (0.51, 2.55)	Moderate	1.14 (0.51, 2.55)	Very Low**

Table 6. Sensitivity analysis based on dose of medication (for primary endpoints NS if RR's 95% CI overlaps 1, for secondary endpoints NS if RR's 95% CI overlaps 0)

Drug	Responders with ≥ 3 CSBM			Responders with <u>increase over baseline by</u> ≥ 1 CSBM			Δb CSBM/wk			Δb SBM/wk		
	Standard	Low	High	Standard	Low	High	Standard	Low	High	Standard	Low	High
Bisacodyl v Placebo	2.46 (1.81, 3.35)	-	-	2.04 (1.62, 2.57)	-	-	3.2 (2.66, 3.74)	-	-	4.90 (4.14, 5.66)	-	-
Na P v Placebo	2.83 (1.93, 4.16)	-	-	2.03 (1.56, 2.64)	-	-	2.0 (1.51, 2.49)	-	-	3.20 (2.55, 3.85)	-	-
Prucalopride v Placebo	2.04 (1.59, 2.62)	1.31 (0.56, 3.04)	2.23 (1.74, 2.85)	1.54 (1.24, 1.92)	1.81 (1.23, 2.66)	1.71 (1.45, 2.01)	0.88 (0.49, 1.28)	1.30 (0.76, 1.84)	0.9 (0.42, 1.38)	1.58 (0.72, 2.44)	1.85 (0.79, 2.91)	1.63 (0.46, 2.81)
Tegaserod v Placebo	1.75 (1.32, 2.33)	1.18 (0.86, 1.62)	-	1.41 (1.18, 1.69)	1.17 (0.96, 1.42)	-	-	-	-	-	-	-
Velusetrag v Placebo	4.09 (1.59, 10.51)	5.57 (2.24, 13.86)	4.9 (1.93, 12.43)	2.49 (1.38, 4.46)	3.33 (1.91, 5.80)	3.5 (2.01, 6.10)	-	-	-	1.90 (1.23, 2.57)	2.20 (1.55, 2.85)	2.10 (1.35, 2.85)
Linaclotide v Placebo	1.92 (1.03, 3.57)	-	2.0 (1.08, 3.69)	1.64 (1.07, 2.51)	-	1.81 (1.19, 2.73)	1.45 (1.09, 1.82)	1.02 (0.22, 1.82)	1.70 (1.39, 2.01)	1.83 (1.18, 2.48)	-	2.26 (1.84, 2.68)
Elobixibat v Placebo	-	-	-	2.25 (1.42, 3.58)	1.74 (1.06, 2.87)	2.25 (1.42, 3.58)	1.46 (0.54, 2.38)	1.42 (0.25, 2.59)	3.09 (2.05, 4.13)	1.79 (0.72, 2.86)	1.18 (-0.06, 2.42)	3.27 (2.11, 4.43)
Lubiprostone v placebo	-	-	-	-	-	-	-	-	-	1.92 (1.35, 2.49)	-	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Drug: Standard dose, Low dose, High dose. Prucalopride: 2mg QD, 1 mg QD, 4mg QD.
Velusetrag: 30mg QD, 15mg QD, 50mg QD. Tegaserod: 6mg bid, 2mg bid, no high dose.
Linaclotide: 145/150mcg QD, 75mcg QD, 290/600mcg QD.
Elobixibat: 10mg QD, 5mg QD, 15mg QD. Lubiprostone: 24mcg bid, no low and high dose.

Confidential: For Review Only

FIGURE LEGENDS

Figure 1: Flow diagram of included studies identified for systematic review.

Figure 2: Network diagram (CT=clinical trials, P=patients)

Figure 3: Comparisons between treatment vs. placebo of primary endpoints, ≥ 3 CSBM/week (panel A) or increase over baseline by >1 CSBM/week (panel B), and secondary endpoints, change in CSBM from baseline (panel C) and change in SBM from baseline (panel D).